{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:43:42Z","timestamp":1780454622015,"version":"3.54.1"},"reference-count":288,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-025-03234-0","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:19:41Z","timestamp":1761862781000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Expanding the Arsenal of Nanocarriers Against Parkinson Disease: Success so Far Roads Ahead"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4890-2428","authenticated-orcid":false,"given":"Naina","family":"Devi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0385-4808","authenticated-orcid":false,"given":"Sonia","family":"Dhiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6718-5183","authenticated-orcid":false,"given":"Chander","family":"Parkash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2979-1590","authenticated-orcid":false,"given":"Thakur Gurjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"issue":"Suppl 1","key":"3234_CR1","first-page":"S26","volume":"66","author":"DM Radhakrishnan","year":"2018","unstructured":"Radhakrishnan DM, Goyal V. Parkinson\u2019s disease: a review. Neurol India. 2018;66(Suppl 1):S26-35.","journal-title":"Neurol India"},{"issue":"1","key":"3234_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/bmb\/ldn013","volume":"86","author":"CA Davie","year":"2008","unstructured":"Davie CA. A review of Parkinson\u2019s disease. Br Med Bull. 2008;86(1):109\u201327.","journal-title":"Br Med Bull"},{"issue":"1","key":"3234_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-020-0110-8","volume":"6","author":"J Tran","year":"2020","unstructured":"Tran J, Anastacio H, Bardy C. Genetic predispositions of Parkinson\u2019s disease revealed in patient-derived brain cells. NPJ Parkinsons Dis. 2020;6(1): 8.","journal-title":"NPJ Parkinsons Dis"},{"key":"3234_CR4","doi-asserted-by":"crossref","unstructured":"Ibrahim NM, Lin CH. Early Onset Parkinsonism: Differential diagnosis and what not to miss. Parkinsonism Relat Disord. 2024;129:107100.","DOI":"10.1016\/j.parkreldis.2024.107100"},{"key":"3234_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/B978-0-444-64012-3.00009-5","volume":"165","author":"G Fabbrini","year":"2019","unstructured":"Fabbrini G, Fabbrini A, Suppa A. Progressive supranuclear palsy, multiple system atrophy and corticobasal degeneration. Handb Clin Neurol. 2019;165:155\u201377.","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"3234_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ncl.2014.09.012","volume":"33","author":"M Stamelou","year":"2015","unstructured":"Stamelou M, Bhatia KP. Atypical parkinsonism: diagnosis and treatment. Neurol Clin. 2015;33(1):39\u201356.","journal-title":"Neurol Clin"},{"key":"3234_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/B978-0-12-804766-8.00016-9","volume":"167","author":"MJ Armstrong","year":"2019","unstructured":"Armstrong MJ, McFarland N. Recognizing and treating atypical Parkinson disorders. Handb Clin Neurol. 2019;167:301\u201320.","journal-title":"Handb Clin Neurol"},{"issue":"9","key":"3234_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26094451","volume":"26","author":"M Lucchesi","year":"2025","unstructured":"Lucchesi M, Biso L, Bonaso M, Longoni B, Buchignani B, Battini R, et al. Mitochondrial dysfunction in genetic and non-genetic Parkinson\u2019s disease. Int J Mol Sci. 2025;26(9):4451.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3234_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1515\/reveh-2021-0111","volume":"38","author":"T Chambers-Richards","year":"2023","unstructured":"Chambers-Richards T, Su Y, Chireh B, D\u2019Arcy C. Exposure to toxic occupations and their association with Parkinson\u2019s disease: a systematic review with meta-analysis. Rev Environ Health. 2023;38(1):65\u201383.","journal-title":"Rev Environ Health"},{"issue":"16","key":"3234_CR10","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1212\/WNL.0000000000000879","volume":"83","author":"B Ritz","year":"2014","unstructured":"Ritz B, Lee P-C, Lassen CF, Arah OA. Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease. Neurology. 2014;83(16):1396\u2013402.","journal-title":"Neurology"},{"issue":"3","key":"3234_CR11","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/ana.10277","volume":"52","author":"MA Hern\u00e1n","year":"2002","unstructured":"Hern\u00e1n MA, Takkouche B, Caama\u00f1o-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson\u2019s disease. Ann Neurol. 2002;52(3):276\u201384.","journal-title":"Ann Neurol"},{"key":"3234_CR12","doi-asserted-by":"crossref","unstructured":"Su D, Cui Y, He C, Zhu J, Yin P, Lam JS, et al. Projections for prevalence of Parkinson's disease and its driving factors in 204 countries and territories to 2050: a systematic analysis of the global burden of disease study. 2019;388:e080952.","DOI":"10.1136\/bmj-2024-080952"},{"issue":"3","key":"3234_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurop.2024.100153","volume":"4","author":"P Salles","year":"2024","unstructured":"Salles P, Tirapegui J, Chan\u00e1-Cuevas P. Genetics of Parkinson\u2019s disease: dominant forms and GBA. Neurol Perspect. 2024;4(3):100153.","journal-title":"Neurol Perspect"},{"key":"3234_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2024.172838","author":"A Aravindan","year":"2024","unstructured":"Aravindan A, Newell ME, Halden RU. Literature review and meta-analysis of environmental toxins associated with increased risk of Parkinson\u2019s disease. Sci Total Environ. 2024. https:\/\/doi.org\/10.1016\/j.scitotenv.2024.172838.","journal-title":"Sci Total Environ"},{"issue":"5","key":"3234_CR15","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/mds.27360","volume":"33","author":"AE Lang","year":"2018","unstructured":"Lang AE, Espay AJ. Disease modification in Parkinson\u2019s disease: current approaches, challenges, and future considerations. Mov Disord. 2018;33(5):660\u201377.","journal-title":"Mov Disord"},{"issue":"11","key":"3234_CR16","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","volume":"32","author":"WM Pardridge","year":"2012","unstructured":"Pardridge WM. Drug transport across the blood\u2013brain barrier. J Cereb Blood Flow Metab. 2012;32(11):1959\u201372.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"9996","key":"3234_CR17","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE. Parkinson\u2019s disease. Lancet. 2015;386(9996):896\u2013912.","journal-title":"Lancet"},{"issue":"1","key":"3234_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1586\/14737175.2014.868306","volume":"14","author":"A Ramirez-Zamora","year":"2014","unstructured":"Ramirez-Zamora A, Molho E. Treatment of motor fluctuations in Parkinson\u2019s disease: recent developments and future directions. Expert Rev Neurother. 2014;14(1):93\u2013103.","journal-title":"Expert Rev Neurother"},{"issue":"6","key":"3234_CR19","first-page":"507","volume":"13","author":"N Borkar","year":"2018","unstructured":"Borkar N, Mu H, Holm R. Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson\u2019s disease. Asian J Pharm Sci. 2018;13(6):507\u201317.","journal-title":"Asian J Pharm Sci"},{"issue":"1","key":"3234_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0022-510X(98)00307-4","volume":"163","author":"JP Bennett Jr.","year":"1999","unstructured":"Bennett JP Jr., Piercey MF. Pramipexole\u2014a new dopamine agonist for the treatment of Parkinson\u2019s disease. J Neurol Sci. 1999;163(1):25\u201331.","journal-title":"J Neurol Sci"},{"key":"3234_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108392","volume":"245","author":"M Ferraiolo","year":"2023","unstructured":"Ferraiolo M, Hermans E. The complex molecular pharmacology of the dopamine D2 receptor: implications for pramipexole, ropinirole, and rotigotine. Pharmacol Ther. 2023;245:108392.","journal-title":"Pharmacol Ther"},{"issue":"6","key":"3234_CR22","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1586\/14737175.2015.1036743","volume":"15","author":"G Mustafa","year":"2015","unstructured":"Mustafa G, Ahuja A, Al Rohaimi AH, Muslim S, Hassan AA, Baboota S, Ali J. Nano-ropinirole for the management of Parkinsonism: blood\u2013brain pharmacokinetics and carrier localization. Expert Rev Neurother. 2015;15(6):695\u2013710.","journal-title":"Expert Rev Neurother"},{"key":"3234_CR23","doi-asserted-by":"crossref","unstructured":"Vadlamudi HC, Yalavarthi PR, Venkata BRM, Thanniru J, KR V, CR S. Potential of microemulsified entacapone drug delivery systems in the management of acute Parkinson's disease. J Acute Dis. 2016;5(4):315\u201325.","DOI":"10.1016\/j.joad.2016.05.004"},{"key":"3234_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.taap.2017.03.013","volume":"323","author":"D Gon\u00e7alves","year":"2017","unstructured":"Gon\u00e7alves D, Alves G, Fortuna A, Soares-da-Silva P, Falc\u00e3o A. Pharmacokinetics of opicapone, a third-generation COMT inhibitor, after single and multiple oral administration: a comparative study in the rat. Toxicol Appl Pharmacol. 2017;323:9\u201315.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"5","key":"3234_CR25","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1021\/acsptsci.4c00124","volume":"7","author":"M Pinto","year":"2024","unstructured":"Pinto M, Silva TB, Sard\u00e3o VA, Sim\u00f5es R, Albuquerque B, Oliveira PJ, et al. Cellular and mitochondrial toxicity of Tolcapone, Entacapone, and new nitrocatechol derivatives. ACS Pharmacol Transl Sci. 2024;7(5):1637\u201349.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"3","key":"3234_CR26","first-page":"467","volume":"3","author":"S Lecht","year":"2007","unstructured":"Lecht S, Haroutiunian S, Hoffman A, Lazarovici P. Rasagiline\u2013a novel MAO B inhibitor in Parkinson\u2019s disease therapy. Ther Clin Risk Manag. 2007;3(3):467\u201374.","journal-title":"Ther Clin Risk Manag"},{"key":"3234_CR27","doi-asserted-by":"crossref","unstructured":"Sharaf J, Williams K-AD, Tariq M, Acharekar MV, Saldivia SEG, Unnikrishnan S, et al. The efficacy of safinamide in the management of Parkinson's disease: a systematic review. Cureus. 2022;14(9):e29118.","DOI":"10.7759\/cureus.29118"},{"issue":"3","key":"3234_CR28","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.drudis.2018.01.033","volume":"23","author":"FG Teixeira","year":"2018","unstructured":"Teixeira FG, Gago MF, Marques P, Moreira PS, Magalh\u00e3es R, Sousa N, Salgado AJ. Safinamide: a new hope for Parkinson\u2019s disease? Drug Discov Today. 2018;23(3):736\u201344.","journal-title":"Drug Discov Today"},{"key":"3234_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/B978-0-12-386467-3.00004-2","volume":"100","author":"K Magyar","year":"2011","unstructured":"Magyar K. The pharmacology of selegiline. Int Rev Neurobiol. 2011;100:65\u201384.","journal-title":"Int Rev Neurobiol"},{"issue":"3","key":"3234_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3233\/JPD-130186","volume":"3","author":"D Salat","year":"2013","unstructured":"Salat D, Tolosa E. Levodopa in the treatment of Parkinson\u2019s disease: current status and new developments. J Parkinsons Dis. 2013;3(3):255\u201369.","journal-title":"J Parkinsons Dis"},{"key":"3234_CR31","unstructured":"https:\/\/www.statpearls.com\/point-of-care\/18221. Accessed 30 Sept 2025."},{"key":"3234_CR32","unstructured":"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519488\/. Accessed 30 Sept 2025."},{"issue":"8","key":"3234_CR33","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","volume":"91","author":"J Jankovic","year":"2020","unstructured":"Jankovic J, Tan EK. Parkinson\u2019s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020;91(8):795\u2013808.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3234_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1535682","volume":"12","author":"VK Yadav","year":"2025","unstructured":"Yadav VK, Dhanasekaran S, Choudhary N, Nathiya D, Thakur V, Gupta R, et al. Recent advances in nanotechnology for Parkinson\u2019s disease: diagnosis, treatment, and future perspectives. Front Med. 2025;12:1535682.","journal-title":"Front Med"},{"issue":"2","key":"3234_CR35","first-page":"e54671","volume":"16","author":"T Grancharova","year":"2024","unstructured":"Grancharova T, Simeonova S, Pilicheva B, Zagorchev P. Gold nanoparticles in Parkinson\u2019s disease therapy: a focus on plant-based green synthesis. Cureus. 2024;16(2):e54671.","journal-title":"Cureus"},{"issue":"1","key":"3234_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/nyas.12403","volume":"1313","author":"S Tinkle","year":"2014","unstructured":"Tinkle S, McNeil SE, M\u00fchlebach S, Bawa R, Borchard G, Barenholz Y, et al. Nanomedicines: addressing the scientific and regulatory gap. Ann N Y Acad Sci. 2014;1313(1):35\u201356.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"3234_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3(1):1\u201321.","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"3234_CR38","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41582-024-01034-x","volume":"20","author":"F Stocchi","year":"2024","unstructured":"Stocchi F, Bravi D, Emmi A, Antonini A. Parkinson disease therapy: current strategies and future research priorities. Nat Rev Neurol. 2024;20(12):695. https:\/\/doi.org\/10.1038\/s41582-024-01034-x.","journal-title":"Nat Rev Neurol"},{"key":"3234_CR39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejphar.2015.01.030","volume":"750","author":"AK Kakkar","year":"2015","unstructured":"Kakkar AK, Dahiya N. Management of Parkinson\u05f3 s disease: current and future pharmacotherapy. Eur J Pharmacol. 2015;750:74\u201381.","journal-title":"Eur J Pharmacol"},{"issue":"14","key":"3234_CR40","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1001\/jama.2020.1224","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS. Choosing a Parkinson disease treatment. JAMA. 2020;323(14):1420.","journal-title":"JAMA"},{"issue":"7","key":"3234_CR41","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.drudis.2015.02.009","volume":"20","author":"G Leyva-Gomez","year":"2015","unstructured":"Leyva-Gomez G, Cortes H, Magana JJ, Leyva-Garc\u00eda N, Quintanar-Guerrero D, Flor\u00e1n B. Nanoparticle technology for treatment of Parkinson\u2019s disease: the role of surface phenomena in reaching the brain. Drug Discov Today. 2015;20(7):824\u201337.","journal-title":"Drug Discov Today"},{"key":"3234_CR42","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jconrel.2018.12.036","volume":"295","author":"PV Torres-Ortega","year":"2019","unstructured":"Torres-Ortega PV, Saludas L, Hanafy AS, Garbayo E, Blanco-Prieto MJ. Micro-and nanotechnology approaches to improve Parkinson\u2019s disease therapy. J Control Release. 2019;295:201\u201313.","journal-title":"J Control Release"},{"key":"3234_CR43","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","volume":"235","author":"C Saraiva","year":"2016","unstructured":"Saraiva C, Pra\u00e7a C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: overcoming blood\u2013brain barrier to treat neurodegenerative diseases. J Control Release. 2016;235:34\u201347.","journal-title":"J Control Release"},{"key":"3234_CR44","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.ijpharm.2019.01.056","volume":"559","author":"G Sharma","year":"2019","unstructured":"Sharma G, Sharma AR, Lee S-S, Bhattacharya M, Nam J-S, Chakraborty C. Advances in nanocarriers enabled brain targeted drug delivery across blood brain barrier. Int J Pharm. 2019;559:360\u201372.","journal-title":"Int J Pharm"},{"issue":"1","key":"3234_CR45","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2174\/1872210516666220228150624","volume":"17","author":"AM Alenzi","year":"2023","unstructured":"Alenzi AM, Albalawi SA, Alghamdi SG, Albalawi RF, Albalawi HS, Qushawy M. Review on different vesicular drug delivery systems (VDDSs) and their applications. Recent Pat Nanotechnol. 2023;17(1):18\u201332.","journal-title":"Recent Pat Nanotechnol"},{"key":"3234_CR46","doi-asserted-by":"crossref","unstructured":"Biju S, Talegaonkar S, Mishra P, Khar R. Vesicular systems: an overview. Indian J Pharm Sci. 2006;68(2):141\u2013153.","DOI":"10.4103\/0250-474X.25707"},{"issue":"3","key":"3234_CR47","first-page":"704","volume":"2","author":"S Bansal","year":"2012","unstructured":"Bansal S, Kashyap CP, Aggarwal G, Harikumar S. A comparative review on vesicular drug delivery system and stability issues. Int J Res Pharm Chem. 2012;2(3):704\u201313.","journal-title":"Int J Res Pharm Chem"},{"issue":"3","key":"3234_CR48","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s13534-021-00198-5","volume":"11","author":"M-W Seo","year":"2021","unstructured":"Seo M-W, Park T-E. Recent advances with liposomes as drug carriers for treatment of neurodegenerative diseases. Biomed Eng Lett. 2021;11(3):211\u20136.","journal-title":"Biomed Eng Lett"},{"issue":"6","key":"3234_CR49","doi-asserted-by":"publisher","first-page":"400","DOI":"10.22270\/jddt.v8i6.2071","volume":"8","author":"H Mishra","year":"2018","unstructured":"Mishra H, Chauhan V, Kumar K, Teotia D. A comprehensive review on liposomes: a novel drug delivery system. J Drug Deliv Therapeutics. 2018;8(6):400\u20134.","journal-title":"J Drug Deliv Therapeutics"},{"issue":"7","key":"3234_CR50","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1080\/1061186X.2018.1527337","volume":"27","author":"KS Ahmed","year":"2019","unstructured":"Ahmed KS, Hussein SA, Ali AH, Korma SA, Lipeng Q, Jinghua C. Liposome: composition, characterisation, preparation, and recent innovation in clinical applications. J Drug Target. 2019;27(7):742\u201361.","journal-title":"J Drug Target"},{"key":"3234_CR51","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40005-016-0260-1","volume":"46","author":"J-S Kim","year":"2016","unstructured":"Kim J-S. Liposomal drug delivery system. J Pharm Investig. 2016;46:387\u201392.","journal-title":"J Pharm Investig"},{"issue":"4","key":"3234_CR52","first-page":"176","volume":"9","author":"Z Huang","year":"2014","unstructured":"Huang Z, Li X, Zhang T, Song Y, She Z, Li J, Deng Y. Progress involving new techniques for liposome preparation. Asian J Pharm Sci. 2014;9(4):176\u201382.","journal-title":"Asian J Pharm Sci"},{"issue":"2","key":"3234_CR53","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1158\/0008-5472.CAN-09-2501","volume":"30","author":"X Huang","year":"2010","unstructured":"Huang X, Caddell R, Yu B, Xu S, Theobald B, Lee LJ, Lee RJ. Ultrasound-enhanced microfluidic synthesis of liposomes. Anticancer Res. 2010;30(2):463\u20136.","journal-title":"Anticancer Res"},{"key":"3234_CR54","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0076-6879(09)65007-2","volume":"465","author":"B Yu","year":"2009","unstructured":"Yu B, Lee RJ, Lee LJ. Microfluidic methods for production of liposomes. Methods Enzymol. 2009;465:129\u201341.","journal-title":"Methods Enzymol"},{"key":"3234_CR55","doi-asserted-by":"crossref","unstructured":"Hamilton RL, Guo LS. French pressure cell liposomes: preparation, properties, and potential. 1st ed. Liposome Technology: CRC Press. 2019. p. 37\u201349.","DOI":"10.1201\/9781351074100-4"},{"key":"3234_CR56","volume":"64","author":"LA Morton","year":"2012","unstructured":"Morton LA, Saludes JP, Yin H. Constant pressure-controlled extrusion method for the preparation of nano-sized lipid vesicles. Journal of visualized experiments: JoVE. 2012;64:4151.","journal-title":"Journal of visualized experiments: JoVE"},{"issue":"3","key":"3234_CR57","doi-asserted-by":"publisher","first-page":"01","DOI":"10.18231\/j.joapr.2021.v9.i3.1-7","volume":"3","author":"B Pradhan","year":"2015","unstructured":"Pradhan B, Kumar N, Saha S, Roy A. Liposome: method of preparation, advantages, evaluation and its application. J Appl Pharm Res. 2015;3(3):01\u20138.","journal-title":"J Appl Pharm Res"},{"key":"3234_CR58","doi-asserted-by":"publisher","unstructured":"Antimisiaris SG. Preparation of DRV liposomes. Liposomes: Methods and Protocols: Springer. 2016;23\u201347. https:\/\/doi.org\/10.1007\/978-1-0716-2954-3_2.","DOI":"10.1007\/978-1-0716-2954-3_2"},{"issue":"9","key":"3234_CR59","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1080\/07373937.2013.769003","volume":"31","author":"RD Jangle","year":"2013","unstructured":"Jangle RD, Thorat BN. Effect of freeze-thawing study on curcumin liposome for obtaining better freeze-dried product. Drying Technol. 2013;31(9):966\u201374.","journal-title":"Drying Technol"},{"key":"3234_CR60","doi-asserted-by":"crossref","unstructured":"Du G, Sun X. Ethanol injection method for liposome preparation. Liposomes: Methods Mol Biol. 2023;2622:65\u201370.","DOI":"10.1007\/978-1-0716-2954-3_5"},{"issue":"3","key":"3234_CR61","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0307-4412(87)90052-5","volume":"15","author":"JC Mathai","year":"1987","unstructured":"Mathai JC, Sitaraman V. Preparation of large uni-lamellar liposomes by the ether injection method and evaluation of the physical integrity by osmometry. Biochemical Education. 1987;15(3):147\u20139.","journal-title":"Biochemical Education"},{"key":"3234_CR62","doi-asserted-by":"crossref","unstructured":"Jing W, Noh H, Tan TJ, Wu NC, Han H-S. Systematic investigation of double emulsion dewetting dynamics for the droplet microfluidic production of Giant Unilamellar Vesicles (GUVs) under biocompatible conditions. bioRxiv. 2025;4:2025\u201302.","DOI":"10.1101\/2025.02.04.636495"},{"issue":"44","key":"3234_CR63","doi-asserted-by":"publisher","first-page":"23521","DOI":"10.1021\/acs.langmuir.4c03322","volume":"40","author":"N Wehrle","year":"2024","unstructured":"Wehrle N, Tran LM, Zheng A, Pissay R, Park YC. Effect of solvent and cholesterol on liposome production by the reverse-phase evaporation (RPE) method. Langmuir. 2024;40(44):23521\u20138.","journal-title":"Langmuir"},{"key":"3234_CR64","doi-asserted-by":"crossref","unstructured":"Schubert R. Liposome preparation by detergent removal. Methods Enzymol. 2003;367:46\u201370.","DOI":"10.1016\/S0076-6879(03)67005-9"},{"issue":"6","key":"3234_CR65","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1073\/pnas.1324135111","volume":"111","author":"S Sur","year":"2014","unstructured":"Sur S, Fries AC, Kinzler KW, Zhou S, Vogelstein B. Remote loading of preencapsulated drugs into stealth liposomes. Proc Natl Acad Sci USA. 2014;111(6):2283\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17","key":"3234_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713542","volume":"24","author":"S Pisani","year":"2023","unstructured":"Pisani S, Di Martino D, Cerri S, Genta I, Dorati R, Bertino G, et al. Investigation and comparison of active and passive encapsulation methods for loading proteins into liposomes. Int J Mol Sci. 2023;24(17):13542.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"3234_CR67","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1038\/s41380-020-0742-4","volume":"26","author":"M Kahana","year":"2021","unstructured":"Kahana M, Weizman A, Gabay M, Loboda Y, Segal-Gavish H, Gavish A, et al. Liposome-based targeting of dopamine to the brain: a novel approach for the treatment of Parkinson\u2019s disease. Mol Psychiatry. 2021;26(6):2626\u201332.","journal-title":"Mol Psychiatry"},{"key":"3234_CR68","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jconrel.2018.03.019","volume":"277","author":"M Qu","year":"2018","unstructured":"Qu M, Lin Q, He S, Wang L, Fu Y, Zhang Z, et al. A brain targeting functionalized liposomes of the dopamine derivative N-3, 4-bis (pivaloyloxy)-dopamine for treatment of Parkinson\u2019s disease. J Control Release. 2018;277:173\u201382.","journal-title":"J Control Release"},{"key":"3234_CR69","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.actbio.2020.11.015","volume":"119","author":"Y-C Kuo","year":"2021","unstructured":"Kuo Y-C, Wang I-H, Rajesh R. Use of leptin-conjugated phosphatidic acid liposomes with resveratrol and epigallocatechin gallate to protect dopaminergic neurons against apoptosis for Parkinson\u2019s disease therapy. Acta Biomater. 2021;119:360\u201374.","journal-title":"Acta Biomater"},{"issue":"51","key":"3234_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202304654","volume":"35","author":"M Sela","year":"2023","unstructured":"Sela M, Poley M, Mora-Raimundo P, Kagan S, Avital A, Kaduri M, et al. Brain-targeted liposomes loaded with monoclonal antibodies reduce alpha-synuclein aggregation and improve behavioral symptoms in Parkinson\u2019s disease. Adv Mater. 2023;35(51):2304654.","journal-title":"Adv Mater"},{"issue":"1","key":"3234_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-025-03104-8","volume":"23","author":"T-D Nguyen","year":"2025","unstructured":"Nguyen T-D, Khanal S, Lee E, Choi J, Bohara G, Rimal N, et al. Astaxanthin-loaded brain-permeable liposomes for Parkinson\u2019s disease treatment via antioxidant and anti-inflammatory responses. J Nanobiotechnology. 2025;23(1):78.","journal-title":"J Nanobiotechnology"},{"issue":"4","key":"3234_CR72","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1515\/abm-2018-0002","volume":"11","author":"PL Yeo","year":"2017","unstructured":"Yeo PL, Lim CL, Chye SM, Ling AK, Koh RY. Niosomes: a review of their structure, properties, methods of preparation, and medical applications. Asian Biomed. 2017;11(4):301\u201314.","journal-title":"Asian Biomed"},{"issue":"2","key":"3234_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16020223","volume":"16","author":"S Liga","year":"2024","unstructured":"Liga S, Paul C, Moac\u0103 E-A, P\u00e9ter F. Niosomes: composition, formulation techniques, and recent progress as delivery systems in cancer therapy. Pharmaceutics. 2024;16(2): 223.","journal-title":"Pharmaceutics"},{"issue":"3","key":"3234_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17030287","volume":"17","author":"M Lens","year":"2025","unstructured":"Lens M. Niosomes as vesicular nanocarriers in cosmetics: characterisation, development and efficacy. Pharmaceutics. 2025;17(3):287.","journal-title":"Pharmaceutics"},{"key":"3234_CR75","unstructured":"Dave D, Mulla T. Niosomes: a comprehensive review of structure, preparation and application. 2023;12(11):1499\u2013537."},{"issue":"1","key":"3234_CR76","first-page":"7372306","volume":"2016","author":"D Ag Seleci","year":"2016","unstructured":"Ag Seleci D, Seleci M, Walter J-G, Stahl F, Scheper T. Niosomes as nanoparticular drug carriers: fundamentals and recent applications. J Nanomater. 2016;2016(1):7372306.","journal-title":"J Nanomater"},{"issue":"10","key":"3234_CR77","first-page":"231","volume":"8","author":"R Koh","year":"2016","unstructured":"Koh R, Yeo P, Chye S, Ling A. Niosome: a mini review on its structure, properties, methods of preparation and medical applications. J Chem Pharm Res. 2016;8(10):231\u20139.","journal-title":"J Chem Pharm Res"},{"key":"3234_CR78","doi-asserted-by":"crossref","unstructured":"Maurya K, Singh A, Pandey S, Kumar N, Siddhiqui MA. Niosomes: classification, preparation and application. Int J Indigenous Herbs Drugs. 2021;6(1):29\u201332.","DOI":"10.46956\/ijihd.vi.120"},{"issue":"4","key":"3234_CR79","doi-asserted-by":"publisher","first-page":"318","DOI":"10.4103\/0975-7406.120080","volume":"5","author":"S Bansal","year":"2013","unstructured":"Bansal S, Aggarwal G, Chandel P, Harikumar S. Design and development of cefdinir niosomes for oral delivery. J Pharm Bioallied Sci. 2013;5(4):318\u201325.","journal-title":"J Pharm Bioallied Sci"},{"issue":"2","key":"3234_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11020055","volume":"11","author":"X Ge","year":"2019","unstructured":"Ge X, Wei M, He S, Yuan W-E. Advances of non-ionic surfactant vesicles (niosomes) and their application in drug delivery. Pharmaceutics. 2019;11(2): 55.","journal-title":"Pharmaceutics"},{"key":"3234_CR81","doi-asserted-by":"publisher","unstructured":"G DB PV. Recent advances of non-ionic surfactant-based nano-vesicles (niosomes and proniosomes): a brief review of these in enhancing transdermal delivery of drug. Futur J Pharm Sci 2020;6:100. https:\/\/doi.org\/10.1186\/s43094-020-00117-y.","DOI":"10.1186\/s43094-020-00117-y"},{"issue":"1","key":"3234_CR82","doi-asserted-by":"publisher","first-page":"01","DOI":"10.32350\/cpr.21.01","volume":"2","author":"S Javaid","year":"2024","unstructured":"Javaid S, Rana T, Naeem Z, Sajid N. Exploring niosomes: a comprehensive review of their structure, formulation, and biomedical applications. Curr Pharm Res. 2024;2(1):01\u201334.","journal-title":"Curr Pharm Res"},{"issue":"8","key":"3234_CR83","doi-asserted-by":"publisher","first-page":"5155","DOI":"10.1166\/jnn.2017.13799","volume":"17","author":"MS Gunay","year":"2017","unstructured":"Gunay MS, Ozer AY, Erdogan S, Bodard S, Baysal I, Gulhan Z, et al. Development of nanosized, pramipexole-encapsulated liposomes and niosomes for the treatment of Parkinson\u2019s disease. J Nanosci Nanotechnol. 2017;17(8):5155\u201367.","journal-title":"J Nanosci Nanotechnol"},{"key":"3234_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1519649","volume":"15","author":"AA Revankar","year":"2025","unstructured":"Revankar AA, Patil AS, Karishetti R, Chougule KR, Patil P, Salokhe A. Enhanced bioavailability of Quercetin-loaded niosomal in situ gel for the management of Parkinson\u2019s disease. Front Pharmacol. 2025;15: 1519649.","journal-title":"Front Pharmacol"},{"key":"3234_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.101791","volume":"58","author":"V Sita","year":"2020","unstructured":"Sita V, Jadhav D, Vavia P. Niosomes for nose-to-brain delivery of bromocriptine: formulation development, efficacy evaluation and toxicity profiling. J Drug Deliv Sci Technol. 2020;58:101791.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"15","key":"3234_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28155905","volume":"28","author":"M Adnan","year":"2023","unstructured":"Adnan M, Akhter MH, Afzal O, Altamimi AS, Ahmad I, Alossaimi MA, et al. Exploring nanocarriers as treatment modalities for skin cancer. Molecules. 2023;28(15):5905.","journal-title":"Molecules"},{"issue":"1","key":"3234_CR87","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/08982104.2022.2085742","volume":"33","author":"A Jafari","year":"2023","unstructured":"Jafari A, Daneshamouz S, Ghasemiyeh P, Mohammadi-Samani S. Ethosomes as dermal\/transdermal drug delivery systems: applications, preparation and characterization. J Liposome Res. 2023;33(1):34\u201352.","journal-title":"J Liposome Res"},{"issue":"5","key":"3234_CR88","doi-asserted-by":"publisher","first-page":"570","DOI":"10.2174\/1567201817666200826093102","volume":"18","author":"J Lu","year":"2021","unstructured":"Lu J, Guo T, Fan Y, Li Z, He Z, Yin S, Feng N. Recent developments in the principles, modification and application prospects of functionalized ethosomes for topical delivery. Curr Drug Deliv. 2021;18(5):570\u201382.","journal-title":"Curr Drug Deliv"},{"issue":"2","key":"3234_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16020267","volume":"16","author":"E Touitou","year":"2024","unstructured":"Touitou E, Natsheh H. The evolution of emerging nanovesicle technologies for enhanced delivery of molecules into and across the skin. Pharmaceutics. 2024;16(2):267.","journal-title":"Pharmaceutics"},{"issue":"3","key":"3234_CR90","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0168-3659(99)00222-9","volume":"65","author":"E Touitou","year":"2000","unstructured":"Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes\u2014novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release. 2000;65(3):403\u201318.","journal-title":"J Control Release"},{"issue":"7","key":"3234_CR91","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3109\/10717544.2012.724472","volume":"19","author":"M Bragagni","year":"2012","unstructured":"Bragagni M, Mennini N, Maestrelli F, Cirri M, Mura P. Comparative study of liposomes, transfersomes and ethosomes as carriers for improving topical delivery of celecoxib. Drug Deliv. 2012;19(7):354\u201361.","journal-title":"Drug Deliv"},{"issue":"3","key":"3234_CR92","doi-asserted-by":"publisher","first-page":"225","DOI":"10.52711\/2231-5691.2022.00037","volume":"12","author":"MM Maniyar","year":"2022","unstructured":"Maniyar MM, Deshmukh AS, Shelke SJ. Ethosomes: a carrier for transdermal drug delivery system. Asian J Pharm Res. 2022;12(3):225\u20138.","journal-title":"Asian J Pharm Res"},{"issue":"28B","key":"3234_CR93","doi-asserted-by":"publisher","first-page":"62","DOI":"10.9734\/jpri\/2022\/v34i28B36036","volume":"34","author":"SK Rada","year":"2022","unstructured":"Rada SK, Yadav S. Ethosomes: a novel approach in vesicular drug delivery systems. Journal of pharmaceutical research International. 2022;34(28B):62\u201371.","journal-title":"Journal of pharmaceutical research International"},{"issue":"6","key":"3234_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/cosmetics11060191","volume":"11","author":"E Musielak","year":"2024","unstructured":"Musielak E, Krajka-Ku\u017aniak V. Liposomes and ethosomes: comparative potential in enhancing skin permeability for therapeutic and cosmetic applications. Cosmet. 2024;11(6):191.","journal-title":"Cosmet"},{"issue":"5","key":"3234_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17050583","volume":"17","author":"RM Almuqbil","year":"2025","unstructured":"Almuqbil RM, Aldhubiab B. Ethosome-based transdermal drug delivery: its structural components, preparation techniques, and therapeutic applications across metabolic, chronic, and oncological conditions. Pharmaceutics. 2025;17(5):583.","journal-title":"Pharmaceutics"},{"issue":"1","key":"3234_CR96","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2025.2512620","volume":"32","author":"S Gharat","year":"2025","unstructured":"Gharat S, Momin M, Panchal U, Omri A. Novel ethosomal gel formulation for enhanced transdermal delivery of curcumin and cyclosporine: a preclinical approach to rheumatoid arthritis management. Drug Deliv. 2025;32(1): 2512620.","journal-title":"Drug Deliv"},{"issue":"9","key":"3234_CR97","first-page":"25","volume":"6","author":"A Tiwari","year":"2016","unstructured":"Tiwari A, Mishra M, Nayak K, Yadav S, Shukla A. Ethosomes: a novel vesicular carrier system for therapeutic applications. IOSR J Pharm. 2016;6(9):25\u201333.","journal-title":"IOSR J Pharm"},{"key":"3234_CR98","first-page":"25","volume":"10","author":"N Mishra","year":"2020","unstructured":"Mishra N, Tiwari DK, Mishra K, Gupta A, Suman S, Mishra S. Development of intranasal deformable ethosomes of rasagiline mesylate for the effective management of parkinsonism. Int J Pharm Biol Sci. 2020;10:25\u201333.","journal-title":"Int J Pharm Biol Sci"},{"issue":"9","key":"3234_CR99","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.5958\/0974-360X.2020.00767.2","volume":"13","author":"P Sneh","year":"2020","unstructured":"Sneh P, Jyothi D, James JP, Maxwell A. Formulation and optimization of ethosomes loaded with ropinirole hydrochloride: application of quality by design approach. Res J Pharm Technol. 2020;13(9):4339\u201345.","journal-title":"Res J Pharm Technol"},{"key":"3234_CR100","doi-asserted-by":"crossref","unstructured":"D Mishra A, N Patel C, R Shah D. Formulation and optimization of ethosomes for transdermal delivery of ropinirole hydrochloride. Curr Drug Deliv. 2013;10(5):500\u2013516.","DOI":"10.2174\/1567201811310050002"},{"issue":"13","key":"3234_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25132959","volume":"25","author":"H Natsheh","year":"2020","unstructured":"Natsheh H, Touitou E. Phospholipid vesicles for dermal\/transdermal and nasal administration of active molecules: the effect of surfactants and alcohols on the fluidity of their lipid bilayers and penetration enhancement properties. Molecules. 2020;25(13): 2959.","journal-title":"Molecules"},{"issue":"5","key":"3234_CR102","first-page":"1","volume":"3","author":"SD Kumavat","year":"2013","unstructured":"Kumavat SD, Chaudhari YS, Borole P, Duvvuri P, Bubera N, Shenghani K, et al. Transfersomes: a promising approach for transdermal drug delivery system. Asian J Pharm Sci Res. 2013;3(5):1\u201317.","journal-title":"Asian J Pharm Sci Res"},{"issue":"2","key":"3234_CR103","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00210-023-02670-8","volume":"397","author":"HA Simrah","year":"2024","unstructured":"Simrah HA, Usmani SA, Izhar MP. Transfersome, an ultra-deformable lipid-based drug nanocarrier: an updated review with therapeutic applications. Naunyn-Schmiedebergs Arch Pharmacol. 2024;397(2):639\u201373.","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"2","key":"3234_CR104","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15020533","volume":"15","author":"HN ElShagea","year":"2023","unstructured":"ElShagea HN, Makar RR, Salama AH, Elkasabgy NA, Basalious EB. Investigating the targeting power to brain tissues of intranasal rasagiline mesylate-loaded transferosomal in situ gel for efficient treatment of Parkinson\u2019s disease. Pharmaceutics. 2023;15(2): 533.","journal-title":"Pharmaceutics"},{"key":"3234_CR105","doi-asserted-by":"crossref","unstructured":"Riccardi D, Baldino L, Reverchon E. Liposomes, transfersomes and niosomes: production methods and their applications in the vaccinal field. J Transl Med. 2024;22(1):339\u2013351.","DOI":"10.1186\/s12967-024-05160-4"},{"key":"3234_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.105287","volume":"92","author":"AS Chabru","year":"2024","unstructured":"Chabru AS, Salve PS, Ghumare GD, Dhamak RS, Tiwari DR, Waghmare DS. Comparative pharmacokinetic studies of transferosomes loaded gel and pressure sensitive adhesive based patch formulation for transdermal delivery of benztropine mesylate. J Drug Deliv Sci Technol. 2024;92: 105287.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3234_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12249-019-1353-8","volume":"20","author":"HF Salem","year":"2019","unstructured":"Salem HF, Kharshoum RM, Abou-Taleb HA, Naguib DM. Nanosized transferosome-based intranasal in situ gel for brain targeting of resveratrol: formulation, optimization, in vitro evaluation, and in vivo pharmacokinetic study. AAPS PharmSciTech. 2019;20:1\u201314.","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"3234_CR108","doi-asserted-by":"publisher","first-page":"122","DOI":"10.52711\/2231-5691.2021.00023","volume":"11","author":"ND Gidde","year":"2021","unstructured":"Gidde ND, Raut ID, Nitalikar MM, Mohite SK, Magdum CS. Pharmacosomes as drug delivery system: an overview. Asian J Pharm Res. 2021;11(2):122\u20137.","journal-title":"Asian J Pharm Res"},{"issue":"3","key":"3234_CR109","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.powtec.2008.02.018","volume":"187","author":"Ja Varshosaz","year":"2008","unstructured":"Varshosaz Ja, Talari R, Mostafavi S, Nokhodchi A. Dissolution enhancement of gliclazide using in situ micronization by solvent change method. Powder Technol. 2008;187(3):222\u201330.","journal-title":"Powder Technol"},{"issue":"5","key":"3234_CR110","doi-asserted-by":"publisher","first-page":"576","DOI":"10.4103\/0250-474X.78523","volume":"72","author":"A Semalty","year":"2010","unstructured":"Semalty A, Semalty M, Rawat B, Singh D, Rawat M. Development and evaluation of pharmacosomes of aceclofenac. Indian J Pharm Sci. 2010;72(5):576.","journal-title":"Indian J Pharm Sci"},{"issue":"4","key":"3234_CR111","first-page":"135","volume":"2","author":"D Annakula","year":"2010","unstructured":"Annakula D, Errabelli MR, Jukanti R, Bandari S, Veerareddy PR. Provesicular drug delivery systems: an overview and appraisal. Arch Appl Sci Res. 2010;2(4):135\u201346.","journal-title":"Arch Appl Sci Res"},{"issue":"3","key":"3234_CR112","first-page":"102","volume":"3","author":"D Kumar","year":"2012","unstructured":"Kumar D, Arnab D. Pharmacosomes: a potential vesicular drug delivery system. Int Res J Pharm. 2012;3(3):102\u20135.","journal-title":"Int Res J Pharm"},{"issue":"2","key":"3234_CR113","first-page":"113","volume":"37","author":"C M\u00fcller-Goymann","year":"1991","unstructured":"M\u00fcller-Goymann C, Hamann H-J. Pharmacosomes: multilamellar vesicles consisting of pure drug. Eur J Pharm Biopharm. 1991;37(2):113\u20137.","journal-title":"Eur J Pharm Biopharm"},{"issue":"9","key":"3234_CR114","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1007\/s13346-023-01315-w","volume":"13","author":"MH Dawoud","year":"2023","unstructured":"Dawoud MH, Zaafan MA, Saleh SS, Mannaa IM, Sweed NM. Response surface optimization of a cardioprotective compound through pharmacosomal drug delivery system: in vivo bioavailability and cardioprotective activity potential. Drug Deliv Transl Res. 2023;13(9):2315\u201339.","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"3234_CR115","doi-asserted-by":"publisher","DOI":"10.1186\/s43094-024-00665-7","volume":"10","author":"P Gawarkar-Patil","year":"2024","unstructured":"Gawarkar-Patil P, Mahajan B, Pawar A, Dhapte-Pawar V. Cubosomes: evolving platform for intranasal drug delivery of neurotherapeutics. Future J Pharm Sci. 2024;10(1):91.","journal-title":"Future J Pharm Sci"},{"issue":"4","key":"3234_CR116","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.3390\/biomedicines11041114","volume":"11","author":"D Sivadasan","year":"2023","unstructured":"Sivadasan D, Sultan MH, Alqahtani SS, Javed S. Cubosomes in drug delivery\u2014a comprehensive review on its structural components, preparation techniques and therapeutic applications. Biomedicines. 2023;11(4):1114.","journal-title":"Biomedicines"},{"key":"3234_CR117","doi-asserted-by":"publisher","first-page":"076","DOI":"10.30574\/gscbps.2018.5.1.0089","volume":"5","author":"SV Rao","year":"2018","unstructured":"Rao SV, Sravya BN, Padmalatha K. A review on cubosome: the novel drug delivery system. GSC Biol Pharm Sci. 2018;5:076\u201381.","journal-title":"GSC Biol Pharm Sci"},{"issue":"4","key":"3234_CR118","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s12551-023-01089-y","volume":"15","author":"AS Palma","year":"2023","unstructured":"Palma AS, Casadei BR, Lotierzo MC, de Castro RD, Barbosa LRS. A short review on the applicability and use of cubosomes as nanocarriers. Biophys Rev. 2023;15(4):553\u201367.","journal-title":"Biophys Rev"},{"key":"3234_CR119","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1208\/ps050430","volume":"5","author":"E Esposito","year":"2003","unstructured":"Esposito E, Eblovi N, Rasi S, Drechsler M, Di Gregorio GM, Menegatti E, Cortesi R. Lipid-based supramolecular systems for topical application: a preformulatory study. AAPS PharmSci. 2003;5:62\u201376.","journal-title":"AAPS PharmSci"},{"key":"3234_CR120","unstructured":"https:\/\/shop.elsevier.com\/books\/delivery-system-handbook-for-personal-care-and-cosmetic-products\/rosen\/978-0-8155-1504-3. Accessed 30 Sept 2025."},{"issue":"19","key":"3234_CR121","doi-asserted-by":"publisher","first-page":"5748","DOI":"10.1021\/la010161w","volume":"17","author":"PT Spicer","year":"2001","unstructured":"Spicer PT, Hayden KL, Lynch ML, Ofori-Boateng A, Burns JL. Novel process for producing cubic liquid crystalline nanoparticles (cubosomes). Langmuir. 2001;17(19):5748\u201356.","journal-title":"Langmuir"},{"issue":"1\u20132","key":"3234_CR122","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0378-5173(02)00673-7","volume":"253","author":"JY Um","year":"2003","unstructured":"Um JY, Chung H, Kim KS, Kwon IC, Jeong SY. In vitro cellular interaction and absorption of dispersed cubic particles. Int J Pharm. 2003;253(1\u20132):71\u201380.","journal-title":"Int J Pharm"},{"key":"3234_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.106111","volume":"100","author":"S Kakulade","year":"2024","unstructured":"Kakulade S, Kulkarni D, Moravkar K, Zambad S, Tekade A, Chalikwar S. Development, characterization and pharmacokinetic evaluation of selegiline HCl loaded cubosomal thermoreversible mucoadhesive gel for nose to brain delivery. J Drug Deliv Sci Technol. 2024;100: 106111.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"3","key":"3234_CR124","doi-asserted-by":"publisher","DOI":"10.3390\/nano11030563","volume":"11","author":"F Fernandes","year":"2021","unstructured":"Fernandes F, Dias-Teixeira M, Delerue-Matos C, Grosso C. Critical review of lipid-based nanoparticles as carriers of neuroprotective drugs and extracts. Nanomaterials. 2021;11(3):563.","journal-title":"Nanomaterials"},{"issue":"30","key":"3234_CR125","doi-asserted-by":"publisher","first-page":"6345","DOI":"10.1002\/adma.201600554","volume":"28","author":"R Zhang","year":"2016","unstructured":"Zhang R, Li Y, Hu B, Lu Z, Zhang J, Zhang X. Traceable nanoparticle delivery of small interfering RNA and retinoic acid with temporally release ability to control neural stem cell differentiation for Alzheimer\u2019s disease therapy. Adv Mater. 2016;28(30):6345\u201352.","journal-title":"Adv Mater"},{"issue":"3","key":"3234_CR126","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1007\/s10853-019-04079-2","volume":"55","author":"C Yan","year":"2020","unstructured":"Yan C, Hu X, Guan P, Hou T, Chen P, Wan D, et al. Highly biocompatible graphene quantum dots: green synthesis, toxicity comparison and fluorescence imaging. J Mater Sci. 2020;55(3):1198\u2013215.","journal-title":"J Mater Sci"},{"issue":"3","key":"3234_CR127","doi-asserted-by":"publisher","first-page":"447","DOI":"10.17219\/acem\/186846","volume":"34","author":"S Roszkowski","year":"2025","unstructured":"Roszkowski S, Durczynska Z. Advantages and limitations of nanostructures for biomedical applications. Adv Clin Exp Med. 2025;34(3):447\u201356.","journal-title":"Adv Clin Exp Med"},{"issue":"1","key":"3234_CR128","doi-asserted-by":"publisher","DOI":"10.1088\/2632-959X\/ab8075","volume":"1","author":"C Poon","year":"2020","unstructured":"Poon C, Patel AA. Organic and inorganic nanoparticle vaccines for prevention of infectious diseases. Nano Express. 2020;1(1): 012001.","journal-title":"Nano Express"},{"key":"3234_CR129","doi-asserted-by":"crossref","unstructured":"Jayatissa YXGAH, Yu Z, Chen X, Li M. Hydrothermal synthesis of nanomaterials. J Nanomater. 2020;2020:1\u20133.","DOI":"10.1155\/2020\/8917013"},{"key":"3234_CR130","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1007\/BF02646980","volume":"21","author":"H Fecht","year":"1990","unstructured":"Fecht H, Hellstern E, Fu Z, Johnson W. Nanocrystalline metals prepared by high-energy ball milling. Metall Trans A Phys Metall Mater Sci. 1990;21:2333\u20137.","journal-title":"Metall Trans A Phys Metall Mater Sci"},{"key":"3234_CR131","unstructured":"Shukla AK, Iravani S. Green synthesis, characterization and applications of nanoparticles. Elsevier. 2018. p. 513\u2013523."},{"issue":"19","key":"3234_CR132","doi-asserted-by":"publisher","first-page":"10410","DOI":"10.1021\/acs.chemrev.5b00193","volume":"115","author":"X Yang","year":"2015","unstructured":"Yang X, Yang M, Pang B, Vara M, Xia Y. Gold nanomaterials at work in biomedicine. Chem Rev. 2015;115(19):10410\u201388.","journal-title":"Chem Rev"},{"issue":"4","key":"3234_CR133","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.nano.2018.01.020","volume":"14","author":"K Hu","year":"2018","unstructured":"Hu K, Chen X, Chen W, Zhang L, Li J, Ye J, et al. Neuroprotective effect of gold nanoparticles composites in Parkinson\u2019s disease model. Nanomedicine. 2018;14(4):1123\u201336.","journal-title":"Nanomedicine"},{"key":"3234_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphotobiol.2019.111635","volume":"200","author":"J Xue","year":"2019","unstructured":"Xue J, Liu T, Liu Y, Jiang Y, Seshadri VDD, Mohan SK, et al. Neuroprotective effect of biosynthesised gold nanoparticles synthesised from root extract of Paeonia moutan against Parkinson disease\u2013in vitro & in vivo model. Journal of Photochemistry and Photobiology B: Biology. 2019;200:111635.","journal-title":"Journal of Photochemistry and Photobiology B: Biology"},{"issue":"1","key":"3234_CR135","doi-asserted-by":"publisher","DOI":"10.1186\/s40824-023-00347-0","volume":"27","author":"J Xu","year":"2023","unstructured":"Xu J, Chen T-Y, Tai C-H, Hsu S-h. Bioactive self-healing hydrogel based on tannic acid modified gold nano-crosslinker as an injectable brain implant for treating Parkinson\u2019s disease. Biomater Res. 2023;27(1): 8.","journal-title":"Biomater Res"},{"key":"3234_CR136","doi-asserted-by":"publisher","first-page":"7135","DOI":"10.33263\/BRIAC106.71357151","volume":"10","author":"MM Rahman","year":"2020","unstructured":"Rahman MM, Ferdous KS, Ahmed M. Emerging promise of nanoparticle-based treatment for Parkinson\u2019s disease. Biointerface Res Appl Chem. 2020;10:7135\u201351.","journal-title":"Biointerface Res Appl Chem"},{"key":"3234_CR137","doi-asserted-by":"publisher","unstructured":"Shivanna DK, Gopinath G, Hanumanthappa R, Babu YR, Abbigeri MB, Ajanal M, Nanjaiah H. Datura stramonium leaves extract silver nanoparticles regulates PINK1 gene in Parkinson\u2019s disease model of Drosophila melanogaster. 2022. https:\/\/doi.org\/10.21203\/rs.3.rs-1807001\/v1.","DOI":"10.21203\/rs.3.rs-1807001\/v1"},{"issue":"1","key":"3234_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-54464-4","volume":"14","author":"B Mirzaei-Behbahani","year":"2024","unstructured":"Mirzaei-Behbahani B, Meratan AA, Moosakhani B, Mohammad-Zaheri M, Mousavi-Jarrahi Z, Nikfarjam N, et al. Efficient inhibition of amyloid fibrillation and cytotoxicity of \u03b1-synuclein and human insulin using biosynthesized silver nanoparticles decorated by green tea polyphenols. Sci Rep. 2024;14(1): 3907.","journal-title":"Sci Rep"},{"key":"3234_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108216","volume":"177","author":"F Naz","year":"2020","unstructured":"Naz F, Fatima M, Naseem S, Khan W, Mondal AC, Siddique YH. Ropinirole silver nanocomposite attenuates neurodegeneration in the transgenic Drosophila melanogaster model of Parkinson\u2019s disease. Neuropharmacology. 2020;177:108216.","journal-title":"Neuropharmacology"},{"issue":"4","key":"3234_CR140","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1444","volume":"9","author":"BA Rzigalinski","year":"2017","unstructured":"Rzigalinski BA, Carfagna CS, Ehrich M. Cerium oxide nanoparticles in neuroprotection and considerations for efficacy and safety. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9(4): e1444.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"2","key":"3234_CR141","first-page":"284","volume":"5","author":"B \u00c7i\u00e7ek","year":"2023","unstructured":"\u00c7i\u00e7ek B, Dan\u0131\u015fman B. Cerium oxide nanoparticles rescue dopaminergic neurons in Parkinson\u2019s disease model of SH-SY5Y cells via modulating Nrf2 signaling and ameliorating apoptotic cell death. ABC Research. 2023;5(2):284\u201390.","journal-title":"ABC Research"},{"key":"3234_CR142","doi-asserted-by":"crossref","unstructured":"Mohammad, Khan UA, Warsi MH, Alkreathy HM, Karim S, Jain GK, Ali A. Intranasal cerium oxide nanoparticles improves locomotor activity and reduces oxidative stress and neuroinflammation in haloperidol-induced parkinsonism in rats. Front Pharmacol. 2023;14:1188470.","DOI":"10.3389\/fphar.2023.1188470"},{"key":"3234_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e21789","author":"X Yao","year":"2024","unstructured":"Yao X, Guan Y, Wang J, Wang D. Cerium oxide nanoparticles modulating the Parkinson\u2019s disease conditions: from the alpha synuclein structural point of view and antioxidant properties of cerium oxide nanoparticles. Heliyon. 2024. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e21789.","journal-title":"Heliyon"},{"issue":"2","key":"3234_CR144","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3390\/nano10020235","volume":"10","author":"R Ruotolo","year":"2020","unstructured":"Ruotolo R, De Giorgio G, Minato I, Bianchi MG, Bussolati O, Marmiroli N. Cerium oxide nanoparticles rescue \u03b1-synuclein-induced toxicity in a yeast model of Parkinson\u2019s disease. Nanomaterials. 2020;10(2):235.","journal-title":"Nanomaterials"},{"issue":"1","key":"3234_CR145","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.drudis.2019.09.020","volume":"25","author":"E Alphand\u00e9ry","year":"2020","unstructured":"Alphand\u00e9ry E. Iron oxide nanoparticles for therapeutic applications. Drug Discov Today. 2020;25(1):141\u20139.","journal-title":"Drug Discov Today"},{"issue":"10","key":"3234_CR146","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s13233-023-00186-x","volume":"31","author":"L Li","year":"2023","unstructured":"Li L, Luo P, Wu S, Wang Y. Deciphering the neuroprotective effect of ascorbic acid mediated synthesis of iron oxide nanoparticles against Parkinson\u2019s disease: an in vitro and in vivo approach. Macromol Res. 2023;31(10):949\u201360.","journal-title":"Macromol Res"},{"issue":"1","key":"3234_CR147","first-page":"81","volume":"27","author":"YA Khadrawy","year":"2024","unstructured":"Khadrawy YA, Hosny EN, Mohamed HSE. Assessment of the neuroprotective effect of green synthesized iron oxide nanoparticles capped with curcumin against a rat model of Parkinson\u2019s disease. Iran J Basic Med Sci. 2024;27(1):81.","journal-title":"Iran J Basic Med Sci"},{"issue":"1","key":"3234_CR148","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1166\/jnn.2016.11103","volume":"16","author":"P Umarao","year":"2016","unstructured":"Umarao P, Bose S, Bhattacharyya S, Kumar A, Jain S. Neuroprotective potential of superparamagnetic iron oxide nanoparticles along with exposure to electromagnetic field in 6-OHDA rat model of Parkinson\u2019s disease. J Nanosci Nanotechnol. 2016;16(1):261\u20139.","journal-title":"J Nanosci Nanotechnol"},{"issue":"6","key":"3234_CR149","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1039\/C7NR06976F","volume":"10","author":"T-H Chung","year":"2018","unstructured":"Chung T-H, Hsu S-C, Wu S-H, Hsiao J-K, Lin C-P, Yao M, Huang D-M. Dextran-coated iron oxide nanoparticle-improved therapeutic effects of human mesenchymal stem cells in a mouse model of Parkinson\u2019s disease. Nanoscale. 2018;10(6):2998\u20133007.","journal-title":"Nanoscale"},{"key":"3234_CR150","doi-asserted-by":"publisher","unstructured":"Saleem MH, Ejaz U, Vithanage M, Bolan N, Siddique KH. Synthesis, characterization, and advanced sustainable applications of copper oxide nanoparticles: a review. Clean Technol Environ Policy. 2024. p. 1\u201326. https:\/\/doi.org\/10.1007\/s10098-024-02774-6.","DOI":"10.1007\/s10098-024-02774-6"},{"key":"3234_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.molliq.2020.115051","volume":"323","author":"J Lyu","year":"2021","unstructured":"Lyu J, Long X, Xie T, Jiang G, Jiang J, Ye L, et al. Copper oxide nanoparticles promote \u03b1-synuclein oligomerization and underlying neurotoxicity as a model of Parkinson\u2019s disease. J Mol Liq. 2021;323:115051.","journal-title":"J Mol Liq"},{"key":"3234_CR152","doi-asserted-by":"crossref","unstructured":"Hanumanthappa R, Venugopal DM, PC N, Shaikh A, BM S, Heggannavar GB, et al. Polyvinylpyrrolidone-capped copper oxide nanoparticles-anchored pramipexole attenuates the rotenone-induced phenotypes in a Drosophila Parkinson\u2019s disease model. ACS Omega. 2023;8(50):47482\u201395.","DOI":"10.1021\/acsomega.3c04312"},{"issue":"4","key":"3234_CR153","doi-asserted-by":"publisher","DOI":"10.3390\/life12040594","volume":"12","author":"H Al Jabri","year":"2022","unstructured":"Al Jabri H, Saleem MH, Rizwan M, Hussain I, Usman K, Alsafran M. Zinc oxide nanoparticles and their biosynthesis: overview. Life. 2022;12(4): 594.","journal-title":"Life"},{"issue":"1","key":"3234_CR154","doi-asserted-by":"publisher","first-page":"19077","DOI":"10.1038\/s41598-024-69324-4","volume":"14","author":"Y Yeni","year":"2024","unstructured":"Yeni Y, Genc S, Ertugrul MS, Nadaroglu H, Gezer A, Mendil AS, et al. Neuroprotective effects of L-Dopa-modified zinc oxide nanoparticles on the rat model of 6-OHDA-\u0131nduced Parkinson\u2019s disease. Sci Rep. 2024;14(1):19077.","journal-title":"Sci Rep"},{"key":"3234_CR155","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20241102","author":"KS Tang","year":"2024","unstructured":"Tang KS, See WZC, Naidu R. Neuroprotective properties of zinc oxide nanoparticles: therapeutic implications for Parkinson\u2019s disease. Biosci Rep. 2024. https:\/\/doi.org\/10.1042\/BSR20241102.","journal-title":"Biosci Rep"},{"issue":"2","key":"3234_CR156","doi-asserted-by":"publisher","first-page":"62","DOI":"10.52547\/CNJ.1.2.62","volume":"1","author":"M Mohammad Ali Mansouri","year":"2023","unstructured":"Mohammad Ali Mansouri M. Effects of zinc oxide nanoparticles on neuronal response of pyramidal neuron of the CA1 hippocampus in rat model of parkinson\u2019s disease. Colloid & Nanoscience Journal. 2023;1(2):62\u201373.","journal-title":"Colloid & Nanoscience Journal"},{"key":"3234_CR157","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3389\/fbioe.2019.00261","volume":"7","author":"S Jesus","year":"2019","unstructured":"Jesus S, Schmutz M, Som C, Borchard G, Wick P, Borges O. Hazard assessment of polymeric nanobiomaterials for drug delivery: what can we learn from literature so far. Front Bioeng Biotechnol. 2019;7:261.","journal-title":"Front Bioeng Biotechnol"},{"key":"3234_CR158","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jconrel.2017.06.019","volume":"261","author":"RS Elezaby","year":"2017","unstructured":"Elezaby RS, Gad HA, Metwally AA, Geneidi AS, Awad GA. Self-assembled amphiphilic core-shell nanocarriers in line with the modern strategies for brain delivery. J Control Release. 2017;261:43\u201361.","journal-title":"J Control Release"},{"key":"3234_CR159","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","volume":"33","author":"D Bobo","year":"2016","unstructured":"Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33:2373\u201387.","journal-title":"Pharm Res"},{"issue":"5","key":"3234_CR160","doi-asserted-by":"publisher","DOI":"10.3390\/polym15051123","volume":"15","author":"M Elmowafy","year":"2023","unstructured":"Elmowafy M, Shalaby K, Elkomy MH, Alsaidan OA, Gomaa HA, Abdelgawad MA, et al. Polymeric nanoparticles for delivery of natural bioactive agents: recent advances and challenges. Polymers. 2023;15(5):1123.","journal-title":"Polymers"},{"issue":"9","key":"3234_CR161","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","volume":"124","author":"MA Beach","year":"2024","unstructured":"Beach MA, Nayanathara U, Gao Y, Zhang C, Xiong Y, Wang Y, Such GK. Polymeric nanoparticles for drug delivery. Chem Rev. 2024;124(9):5505\u2013616.","journal-title":"Chem Rev"},{"issue":"7","key":"3234_CR162","doi-asserted-by":"publisher","DOI":"10.3390\/polym17070833","volume":"17","author":"L Eltaib","year":"2025","unstructured":"Eltaib L. Polymeric nanoparticles in targeted drug delivery: unveiling the impact of polymer characterization and fabrication. Polymers. 2025;17(7): 833.","journal-title":"Polymers"},{"issue":"18","key":"3234_CR163","first-page":"1996","volume":"60","author":"C Adhikari","year":"2021","unstructured":"Adhikari C. Polymer nanoparticles-preparations, applications and future insights: a concise review. Polymer-plastics technology and materials. 2021;60(18):1996\u20132024.","journal-title":"Polymer-plastics technology and materials"},{"issue":"3","key":"3234_CR164","doi-asserted-by":"publisher","DOI":"10.3390\/ph15030370","volume":"15","author":"MZ Ahmad","year":"2022","unstructured":"Ahmad MZ, Sabri AHB, Anjani QK, Dom\u00ednguez-Robles J, Abdul Latip N, Hamid KA. Design and development of levodopa loaded polymeric nanoparticles for intranasal delivery. Pharmaceuticals. 2022;15(3):370.","journal-title":"Pharmaceuticals"},{"issue":"9","key":"3234_CR165","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27092811","volume":"27","author":"BF Mogharbel","year":"2022","unstructured":"Mogharbel BF, Cardoso MA, Irioda AC, Stricker PEF, Slompo RC, Appel JM, et al. Biodegradable nanoparticles loaded with levodopa and curcumin for treatment of Parkinson\u2019s disease. Molecules. 2022;27(9): 2811.","journal-title":"Molecules"},{"key":"3234_CR166","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2015.00020","volume":"7","author":"M Esteves","year":"2015","unstructured":"Esteves M, Crist\u00f3v\u00e3o AC, Saraiva T, Rocha SM, Baltazar G, Ferreira L, Bernardino L. Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model for Parkinson\u2019s disease. Front Aging Neurosci. 2015;7: 20.","journal-title":"Front Aging Neurosci"},{"key":"3234_CR167","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S272831","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Xiong S, Liu P, Liu W, Wang Q, Liu Y, et al. Polymeric nanoparticles-based brain delivery with improved therapeutic efficacy of ginkgolide B in Parkinson\u2019s disease. Int J Nanomedicine. 2020. https:\/\/doi.org\/10.2147\/IJN.S272831.","journal-title":"Int J Nanomedicine"},{"key":"3234_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2023.141399","volume":"458","author":"P Sun","year":"2023","unstructured":"Sun P, Xing Z, Li Z, Zhou W. Recent advances in quantum dots photocatalysts. Chem Eng J. 2023;458:141399.","journal-title":"Chem Eng J"},{"issue":"9","key":"3234_CR169","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s41565-018-0179-y","volume":"13","author":"D Kim","year":"2018","unstructured":"Kim D, Yoo JM, Hwang H, Lee J, Lee SH, Yun SP, et al. Graphene quantum dots prevent \u03b1-synucleinopathy in Parkinson\u2019s disease. Nat Nanotechnol. 2018;13(9):812\u20138.","journal-title":"Nat Nanotechnol"},{"key":"3234_CR170","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1007\/s11426-016-0103-7","volume":"59","author":"L Wang","year":"2016","unstructured":"Wang L, Li X, Han Y, Wang T, Zhao Y, Ali A, et al. Quantum dots protect against MPP+-induced neurotoxicity in a cell model of Parkinson\u2019s disease through autophagy induction. Sci China Chem. 2016;59:1486\u201391.","journal-title":"Sci China Chem"},{"key":"3234_CR171","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2022.102608","volume":"47","author":"P Kaliyaperumal","year":"2023","unstructured":"Kaliyaperumal P, Renganathan S, Arumugam K, Aremu BR. Engineered graphene quantum dot nanocomposite triggers \u03b1-synuclein defibrillation: therapeutics against Parkinson\u2019s disease. Nanomed Nanotechnol Biol Med. 2023;47:102608.","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"3234_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122622","volume":"309","author":"W Guo","year":"2024","unstructured":"Guo W, Ji M, Li Y, Qian M, Qin Y, Li W, et al. Iron ions-sequestrable and antioxidative carbon dot-based nano-formulation with nitric oxide release for Parkinson\u2019s disease treatment. Biomaterials. 2024;309:122622.","journal-title":"Biomaterials"},{"issue":"12","key":"3234_CR173","doi-asserted-by":"publisher","DOI":"10.3390\/polym14122510","volume":"14","author":"S Perumal","year":"2022","unstructured":"Perumal S, Atchudan R, Lee W. A review of polymeric micelles and their applications. Polymers. 2022;14(12): 2510.","journal-title":"Polymers"},{"issue":"10","key":"3234_CR174","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1021\/acs.molpharmaceut.7b00374","volume":"14","author":"T Chen","year":"2017","unstructured":"Chen T, Li Y, Li C, Yi X, Wang R, Lee SM-Y, Zheng Y. Pluronic P85\/F68 micelles of baicalein could interfere with mitochondria to overcome MRP2-mediated efflux and offer improved anti-Parkinsonian activity. Mol Pharm. 2017;14(10):3331\u201342.","journal-title":"Mol Pharm"},{"key":"3234_CR175","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119046","volume":"577","author":"F Wang","year":"2020","unstructured":"Wang F, Yang Z, Liu M, Tao Y, Li Z, Wu Z, et al. Facile nose-to-brain delivery of rotigotine-loaded polymer micelles thermosensitive hydrogels: in vitro characterization and in vivo behavior study. Int J Pharm. 2020;577:119046.","journal-title":"Int J Pharm"},{"issue":"1","key":"3234_CR176","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25010112","volume":"25","author":"S Bayda","year":"2019","unstructured":"Bayda S, Adeel M, Tuccinardi T, Cordani M, Rizzolio F. The history of nanoscience and nanotechnology: from chemical\u2013physical applications to nanomedicine. Molecules. 2019;25(1): 112.","journal-title":"Molecules"},{"issue":"3","key":"3234_CR177","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/bab.2175","volume":"69","author":"V Akbari","year":"2022","unstructured":"Akbari V, Rezazadeh M, Hanaie NS, Hasanzadeh F. Preparation and in vitro characterization of histidine trimethyl chitosan conjugated nanocomplex incorporated into injectable thermosensitive hydrogels for localized gene delivery. Biotechnol Appl Biochem. 2022;69(3):1047\u201357.","journal-title":"Biotechnol Appl Biochem"},{"issue":"7","key":"3234_CR178","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.202000017","volume":"3","author":"DA B\u00f6l\u00fckbas","year":"2020","unstructured":"B\u00f6l\u00fckbas DA, Datz S, Meyer-Schwickerath C, Morrone C, Doryab A, G\u00f6\u00dfl D, et al. Organ-restricted vascular delivery of nanoparticles for lung cancer therapy. Adv Ther. 2020;3(7):2000017.","journal-title":"Adv Ther"},{"issue":"11","key":"3234_CR179","doi-asserted-by":"publisher","first-page":"4582","DOI":"10.1021\/acs.biomac.1c00884","volume":"22","author":"R Ferrer- Lorente","year":"2021","unstructured":"Ferrer-Lorente R, Lozano-Cruz T, Fern\u00e1ndez-Carasa I, Mi\u0142owska K, de la Mata FJ, Bryszewska M, et al. Cationic carbosilane dendrimers prevent abnormal \u03b1-synuclein accumulation in Parkinson\u2019s disease patient-specific dopamine neurons. Biomacromolecules. 2021;22(11):4582\u201391.","journal-title":"Biomacromolecules"},{"key":"3234_CR180","first-page":"45","volume":"38","author":"W Dai","year":"2024","unstructured":"Dai W, Zhan M, Gao Y, Sun H, Zou Y, Laurent R, et al. Brain delivery of fibronectin through bioactive phosphorous dendrimers for Parkinson\u2019s disease treatment via cooperative modulation of microglia. Bioact Mater. 2024;38:45\u201354.","journal-title":"Bioact Mater"},{"issue":"20","key":"3234_CR181","doi-asserted-by":"publisher","first-page":"5529","DOI":"10.7150\/thno.29039","volume":"8","author":"A Sharma","year":"2018","unstructured":"Sharma A, Liaw K, Sharma R, Zhang Z, Kannan S, Kannan RM. Targeting mitochondrial dysfunction and oxidative stress in activated microglia using dendrimer-based therapeutics. Theranostics. 2018;8(20):5529.","journal-title":"Theranostics"},{"key":"3234_CR182","doi-asserted-by":"publisher","first-page":"6165","DOI":"10.1002\/anie.200460649","volume":"43","author":"F Manea","year":"2004","unstructured":"Manea F, Houillon F, Pasquato L, Scrimin P. Nanozymes: gold-nanoparticle-based transphosphorylation catalysts. Angew Chem Int Ed. 2004;43:6165\u20139.","journal-title":"Angew Chem Int Ed"},{"key":"3234_CR183","doi-asserted-by":"crossref","unstructured":"Wang X, Guo W, Hu Y, Wu J, Wei H. Nanozymes: next wave of artificial enzymes. 1st ed. Springer. 2016. p. 1\u2013126.","DOI":"10.1007\/978-3-662-53068-9_1"},{"key":"3234_CR184","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2020.101027","volume":"36","author":"Y-Q Liu","year":"2021","unstructured":"Liu Y-Q, Mao Y, Xu E, Jia H, Zhang S, Dawson VL, et al. Nanozyme scavenging ROS for prevention of pathologic \u03b1-synuclein transmission in Parkinson\u2019s disease. Nano Today. 2021;36: 101027.","journal-title":"Nano Today"},{"issue":"45","key":"3234_CR185","doi-asserted-by":"publisher","first-page":"14455","DOI":"10.1002\/ange.201708573","volume":"129","author":"N Singh","year":"2017","unstructured":"Singh N, Savanur MA, Srivastava S, D\u2019Silva P, Mugesh G. A redox modulatory Mn3O4 nanozyme with multi-enzyme activity provides efficient cytoprotection to human cells in a Parkinson\u2019s disease model. Angew Chem. 2017;129(45):14455\u20139.","journal-title":"Angew Chem"},{"issue":"37","key":"3234_CR186","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201800202","volume":"30","author":"S Wang","year":"2018","unstructured":"Wang S, McGuirk CM, d\u2019Aquino A, Mason JA, Mirkin CA. Metal\u2013organic framework nanoparticles. Adv Mater. 2018;30(37):1800202.","journal-title":"Adv Mater"},{"issue":"10","key":"3234_CR187","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202303454","volume":"13","author":"Q Li","year":"2024","unstructured":"Li Q, Ding X, Chang Z, Fan X, Pan J, Yang Y, et al. Metal-organic framework based nanozyme system for NLRP3 inflammasome-mediated neuroinflammatory regulation in Parkinson\u2019s disease. Adv Healthc Mater. 2024;13(10):2303454.","journal-title":"Adv Healthc Mater"},{"issue":"1","key":"3234_CR188","doi-asserted-by":"publisher","first-page":"8137","DOI":"10.1038\/s41467-023-43870-3","volume":"14","author":"W Jiang","year":"2023","unstructured":"Jiang W, Li Q, Zhang R, Li J, Lin Q, Li J, et al. Chiral metal-organic frameworks incorporating nanozymes as neuroinflammation inhibitors for managing Parkinson\u2019s disease. Nat Commun. 2023;14(1):8137.","journal-title":"Nat Commun"},{"issue":"2","key":"3234_CR189","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s12274-023-6304-8","volume":"17","author":"X Fan","year":"2024","unstructured":"Fan X, Zhang T, Ding X, Gu Y, Li Q, Jiang W, Fan K. Bioinspired metal-organic framework nanozyme reinforced with thermosensitive hydrogel for regulating inflammatory responses in Parkinson\u2019s disease. Nano Res. 2024;17(2):858\u201365.","journal-title":"Nano Res"},{"issue":"4","key":"3234_CR190","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2174\/1568026615666150108144655","volume":"15","author":"C Comfort","year":"2015","unstructured":"Comfort C, Garrastazu G, Pozzoli M, Sonvico F. Opportunities and challenges for the nasal administration of nanoemulsions. Curr Top Med Chem. 2015;15(4):356\u201368.","journal-title":"Curr Top Med Chem"},{"key":"3234_CR191","doi-asserted-by":"crossref","unstructured":"Gurpreet K, Singh S. Review of nanoemulsion formulation and characterization techniques. Indian J Pharm Sci. 2018;80(5):781\u2013789.","DOI":"10.4172\/pharmaceutical-sciences.1000422"},{"issue":"2","key":"3234_CR192","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3109\/10717544.2013.838014","volume":"21","author":"HS Mahajan","year":"2014","unstructured":"Mahajan HS, Mahajan MS, Nerkar PP, Agrawal A. Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting. Drug Deliv. 2014;21(2):148\u201354.","journal-title":"Drug Deliv"},{"key":"3234_CR193","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jconrel.2017.03.008","volume":"252","author":"Y Singh","year":"2017","unstructured":"Singh Y, Meher JG, Raval K, Khan FA, Chaurasia M, Jain NK, Chourasia MK. Nanoemulsion: concepts, development and applications in drug delivery. J Control Release. 2017;252:28\u201349.","journal-title":"J Control Release"},{"issue":"48","key":"3234_CR194","doi-asserted-by":"publisher","DOI":"10.1088\/0957-4484\/25\/48\/485102","volume":"25","author":"R Pangeni","year":"2014","unstructured":"Pangeni R, Sharma S, Mustafa G, Ali J, Baboota S. Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson\u2019s disease by reducing oxidative stress. Nanotechnology. 2014;25(48): 485102.","journal-title":"Nanotechnology"},{"key":"3234_CR195","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ijbiomac.2020.11.207","volume":"167","author":"N Nehal","year":"2021","unstructured":"Nehal N, Nabi B, Rehman S, Pathak A, Iqubal A, Khan SA, et al. Chitosan coated synergistically engineered nanoemulsion of Ropinirole and nigella oil in the management of Parkinson\u2019s disease: formulation perspective and in vitro and in vivo assessment. Int J Biol Macromol. 2021;167:605\u201319.","journal-title":"Int J Biol Macromol"},{"issue":"4","key":"3234_CR196","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s13596-022-00648-0","volume":"23","author":"K Geetha","year":"2023","unstructured":"Geetha K, Shankar J, Wilson B. Neuroprotective effect of chia seed oil nanoemulsion against rotenone induced motor impairment and oxidative stress in mice model of Parkinson\u2019s disease. Adv Tradit Med. 2023;23(4):1091\u2013108.","journal-title":"Adv Tradit Med"},{"issue":"7","key":"3234_CR197","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11071378","volume":"11","author":"SS Das","year":"2022","unstructured":"Das SS, Sarkar A, Chabattula SC, Verma PRP, Nazir A, Gupta PK, et al. Food-grade quercetin-loaded nanoemulsion ameliorates effects associated with Parkinson\u2019s disease and cancer: studies employing a transgenic c. elegans model and human cancer cell lines. Antioxidants. 2022;11(7):1378.","journal-title":"Antioxidants"},{"issue":"5","key":"3234_CR198","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1089\/rej.2017.2035","volume":"21","author":"S Kumar","year":"2018","unstructured":"Kumar S, Dang S, Nigam K, Ali J, Baboota S. Selegiline nanoformulation in attenuation of oxidative stress and upregulation of dopamine in the brain for the treatment of Parkinson\u2019s disease. Rejuvenation Res. 2018;21(5):464\u201376.","journal-title":"Rejuvenation Res"},{"issue":"7","key":"3234_CR199","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.5958\/0974-360X.2020.00625.3","volume":"13","author":"RS Kumar","year":"2020","unstructured":"Kumar RS, Sureshkumar R. A review on solid supersaturable SNEDDS. Res J Pharm Technol. 2020;13(7):3530\u20135.","journal-title":"Res J Pharm Technol"},{"key":"3234_CR200","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2020.111590","volume":"144","author":"R Kumar","year":"2020","unstructured":"Kumar R, Kumar R, Khurana N, Singh SK, Khurana S, Verma S, et al. Enhanced oral bioavailability and neuroprotective effect of fisetin through its SNEDDS against rotenone-induced Parkinson\u2019s disease rat model. Food Chem Toxicol. 2020;144:111590.","journal-title":"Food Chem Toxicol"},{"issue":"37","key":"3234_CR201","doi-asserted-by":"publisher","DOI":"10.1088\/0957-4484\/27\/37\/375101","volume":"27","author":"S Sharma","year":"2016","unstructured":"Sharma S, Narang JK, Ali J, Baboota S. Synergistic antioxidant action of vitamin E and rutin SNEDDS in ameliorating oxidative stress in a Parkinson\u2019s disease model. Nanotechnology. 2016;27(37): 375101.","journal-title":"Nanotechnology"},{"issue":"2","key":"3234_CR202","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2174\/1872210515666210329161439","volume":"16","author":"R Srivastava","year":"2022","unstructured":"Srivastava R, Choudhury PK, Dev SK, Rathore V. Formulation and Evaluation of \u03b1-Pinene Loaded Self-emulsifying Nanoformulation for In-Vivo Anti-Parkinson\u2019s Activity. Recent Pat Nanotechnol. 2022;16(2):139\u201359.","journal-title":"Recent Pat Nanotechnol"},{"key":"3234_CR203","unstructured":"Abd El Kawy MA, Michel CG, Kirollos FN, El Kerdawy AM, Sedeek M. In vitro MAO-B Inhibitory Effects of Citrus trifoliata L. Fruits Extract, Self-Nano-Emulsifying Drug Delivery System and Isolated Hesperidin: Enzyme Assay and Molecular Docking Study. Egyptian Journal of Chemistry. 2020;63(3):897\u2013906."},{"key":"3234_CR204","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s12017-016-8398-6","volume":"18","author":"L Hang","year":"2016","unstructured":"Hang L, Basil AH, Lim K-L. Nutraceuticals in Parkinson\u2019s disease. Neuromol Med. 2016;18:306\u201321.","journal-title":"Neuromol Med"},{"issue":"7","key":"3234_CR205","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/jnr.22310","volume":"88","author":"H Yokoyama","year":"2010","unstructured":"Yokoyama H, Kuroiwa H, Tsukada T, Uchida H, Kato H, Araki T. Poly (ADP-ribose) polymerase inhibitor can attenuate the neuronal death after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced neurotoxicity in mice. J Neurosci Res. 2010;88(7):1522\u201336.","journal-title":"J Neurosci Res"},{"issue":"10","key":"3234_CR206","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1301\/002966402320583433","volume":"60","author":"A Martin","year":"2002","unstructured":"Martin A, Youdim K, Szprengiel A, Shukitt-Hale B, Joseph J. Roles of vitamins E and C on neurodegenerative diseases and cognitive performance. Nutr Rev. 2002;60(10):308\u201326.","journal-title":"Nutr Rev"},{"issue":"6","key":"3234_CR207","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1474-4422(05)70097-1","volume":"4","author":"M Etminan","year":"2005","unstructured":"Etminan M, Gill SS, Samii A. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson\u2019s disease: a meta-analysis. Lancet Neurol. 2005;4(6):362\u20135.","journal-title":"Lancet Neurol"},{"issue":"7","key":"3234_CR208","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/archneurol.2010.120","volume":"67","author":"P Knekt","year":"2010","unstructured":"Knekt P, Kilkkinen A, Rissanen H, Marniemi J, S\u00e4\u00e4ksj\u00e4rvi K, Heli\u00f6vaara M. Serum vitamin D and the risk of Parkinson disease. Arch Neurol. 2010;67(7):808\u201311.","journal-title":"Arch Neurol"},{"issue":"10","key":"3234_CR209","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1001\/archneur.65.10.1348","volume":"65","author":"ML Evatt","year":"2008","unstructured":"Evatt ML, DeLong MR, Khazai N, Rosen A, Triche S, Tangpricha V. Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol. 2008;65(10):1348\u201352.","journal-title":"Arch Neurol"},{"issue":"1","key":"3234_CR210","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.pharmthera.2005.02.002","volume":"107","author":"CW Shults","year":"2005","unstructured":"Shults CW. Therapeutic role of coenzyme Q10 in Parkinson\u2019s disease. Pharmacol Ther. 2005;107(1):120\u201330.","journal-title":"Pharmacol Ther"},{"issue":"7","key":"3234_CR211","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1212\/01.wnl.0000238518.34389.12","volume":"67","author":"A Bender","year":"2006","unstructured":"Bender A, Koch W, Elstner M, Schombacher Y, Bender J, Moeschl M, et al. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology. 2006;67(7):1262\u20134.","journal-title":"Neurology"},{"key":"3234_CR212","doi-asserted-by":"crossref","unstructured":"Denny Joseph K, Muralidhara. Combined oral supplementation of fish oil and quercetin enhances neuroprotection in a chronic rotenone rat model: relevance to Parkinson\u2019s disease. Neurochem Res. 2015;40:894\u2013905.","DOI":"10.1007\/s11064-015-1542-0"},{"issue":"6","key":"3234_CR213","doi-asserted-by":"publisher","first-page":"432","DOI":"10.2174\/187152709789824642","volume":"8","author":"M Garc\u00eda-Arencibia","year":"2009","unstructured":"Garc\u00eda-Arencibia M, Garc\u00eda C, Fern\u00e1ndez-Ruiz J. Cannabinoids and Parkinson\u2019s disease. CNS & Neurological Disorders. 2009;8(6):432\u20139.","journal-title":"CNS & Neurological Disorders"},{"issue":"9","key":"3234_CR214","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ptr.1514","volume":"18","author":"BV Manyam","year":"2004","unstructured":"Manyam BV, Dhanasekaran M, Hare TA. Neuroprotective effects of the antiparkinson drug Mucuna pruriens. Phytother Res. 2004;18(9):706\u201312.","journal-title":"Phytother Res"},{"key":"3234_CR215","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10722-014-0164-8","volume":"62","author":"R Patil","year":"2015","unstructured":"Patil R, Gholave A, Jadhav J, Yadav S, Bapat V. Mucuna sanjappae Aitawade et Yadav: a new species of Mucuna with promising yield of anti-Parkinson\u2019s drug L-DOPA. Genet Resour Crop Evol. 2015;62:155\u201362.","journal-title":"Genet Resour Crop Evol"},{"key":"3234_CR216","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1096\/fasebj.29.1_supplement.922.9","volume":"29","author":"Q Xu","year":"2015","unstructured":"Xu Q, Kanthasamy A, Reddy M. (\u2212)-Epigallocatechin-3-gallate protects against TNF alpha and hydrogen peroxide induced apoptosis in a cell culture model of Parkinson\u2019s disease. FASEB J. 2015;29:922\u20139.","journal-title":"FASEB J"},{"issue":"5","key":"3234_CR217","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.freeradbiomed.2007.11.011","volume":"44","author":"B Jagatha","year":"2008","unstructured":"Jagatha B, Mythri RB, Vali S, Bharath MS. Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson\u2019s disease explained via in silico studies. Free Radic Biol Med. 2008;44(5):907\u201317.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"3234_CR218","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1089\/rej.2009.0908","volume":"13","author":"S Yu","year":"2010","unstructured":"Yu S, Zheng W, Xin N, Chi Z-H, Wang N-Q, Nie Y-X, et al. Curcumin prevents dopaminergic neuronal death through inhibition of the c-Jun N-terminal kinase pathway. Rejuvenation Res. 2010;13(1):55\u201364.","journal-title":"Rejuvenation Res"},{"issue":"4","key":"3234_CR219","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.pbb.2009.03.008","volume":"92","author":"X Mu","year":"2009","unstructured":"Mu X, He G, Cheng Y, Li X, Xu B, Du G. Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro. Pharmacol Biochem Behav. 2009;92(4):642\u20138.","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"3234_CR220","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.bbrc.2009.12.079","volume":"391","author":"EA Waxman","year":"2010","unstructured":"Waxman EA, Emmer KL, Giasson BI. Residue Glu83 plays a major role in negatively regulating \u03b1-synuclein amyloid formation. Biochem Biophys Res Commun. 2010;391(3):1415\u201320.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"3234_CR221","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1124\/mol.110.064535","volume":"78","author":"F Zhang","year":"2010","unstructured":"Zhang F, Shi J-S, Zhou H, Wilson B, Hong J-S, Gao H-M. Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions. Mol Pharmacol. 2010;78(3):466\u201377.","journal-title":"Mol Pharmacol"},{"key":"3234_CR222","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s10571-009-9411-5","volume":"29","author":"J Bournival","year":"2009","unstructured":"Bournival J, Quessy P, Martinoli M-G. Protective effects of resveratrol and quercetin against MPP+-induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cell Mol Neurobiol. 2009;29:1169\u201380.","journal-title":"Cell Mol Neurobiol"},{"issue":"2","key":"3234_CR223","first-page":"102","volume":"25","author":"B Jamali","year":"2023","unstructured":"Jamali B, Entezari M, Babaei N, Hashemi M. The evaluation of vitamin E and TiO2 nanoparticles administration in parkinson\u2019s rat model. Cell Journal (Yakhteh). 2023;25(2):102.","journal-title":"Cell Journal (Yakhteh)"},{"issue":"8","key":"3234_CR224","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29081774","volume":"29","author":"R Mallamaci","year":"2024","unstructured":"Mallamaci R, Musar\u00f2 D, Greco M, Caponio A, Castellani S, Munir A, et al. Dopamine-and grape-seed-extract-loaded solid lipid nanoparticles: interaction studies between particles and differentiated SH-SY5Y neuronal cell model of Parkinson\u2019s disease. Molecules. 2024;29(8):1774.","journal-title":"Molecules"},{"issue":"1","key":"3234_CR225","volume":"2019","author":"B Gaba","year":"2019","unstructured":"Gaba B, Khan T, Haider MF, Alam T, Baboota S, Parvez S, et al. Vitamin E loaded naringenin nanoemulsion via intranasal delivery for the management of oxidative stress in a 6-OHDA Parkinson\u2019s disease model. Biomed Res Int. 2019;2019(1):2382563.","journal-title":"Biomed Res Int"},{"key":"3234_CR226","volume":"268","author":"NSG Chaves","year":"2023","unstructured":"Chaves NSG, Janner DE, Poetini MR, Fernandes EJ, de Almeida FP, Musachio EAS, et al. \u0392-carotene-loaded nanoparticles protect against neuromotor damage, oxidative stress, and dopamine deficits in a model of Parkinson\u2019s disease in Drosophila melanogaster. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology. 2023;268:109615.","journal-title":"Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology"},{"issue":"8","key":"3234_CR227","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16081048","volume":"16","author":"S Castellani","year":"2024","unstructured":"Castellani S, Iaconisi GN, Tripaldi F, Porcelli V, Trapani A, Messina E, et al. Dopamine and citicoline-co-loaded solid lipid nanoparticles as multifunctional nanomedicines for Parkinson\u2019s disease treatment by intranasal administration. Pharmaceutics. 2024;16(8): 1048.","journal-title":"Pharmaceutics"},{"issue":"1","key":"3234_CR228","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10561-022-10008-6","volume":"24","author":"M Mobahat","year":"2023","unstructured":"Mobahat M, Sadroddiny E, Nooshabadi VT, Ebrahimi-Barough S, Goodarzi A, Malekshahi ZV, et al. Curcumin-loaded human endometrial stem cells derived exosomes as an effective carrier to suppress alpha-synuclein aggregates in 6OHDA-induced Parkinson\u2019s disease mouse model. Cell Tissue Bank. 2023;24(1):75\u201391.","journal-title":"Cell Tissue Bank"},{"key":"3234_CR229","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.935784","volume":"13","author":"P Parekh","year":"2022","unstructured":"Parekh P, Serra M, Allaw M, Perra M, Marongiu J, Tolle G, et al. Characterization of Nasco grape pomace-loaded nutriosomes and their neuroprotective effects in the MPTP mouse model of Parkinson\u2019s disease. Front Pharmacol. 2022;13:935784.","journal-title":"Front Pharmacol"},{"key":"3234_CR230","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2021.109431","volume":"340","author":"EJ Fernandes","year":"2021","unstructured":"Fernandes EJ, Poetini MR, Barrientos MS, Bortolotto VC, Araujo SM, Musachio EAS, et al. Exposure to lutein-loaded nanoparticles attenuates Parkinson\u2019s model-induced damage in Drosophila melanogaster: restoration of dopaminergic and cholinergic system and oxidative stress indicators. Chem Biol Interact. 2021;340:109431.","journal-title":"Chem Biol Interact"},{"issue":"2","key":"3234_CR231","first-page":"019","volume":"11","author":"M Mani","year":"2021","unstructured":"Mani M, Balasubramanian S, Manikandan KR, Kulandaivel B. Neuroprotective potential of Naringenin-loaded solid-lipid nanoparticles against rotenone-induced Parkinson\u2019s disease model. J Appl Pharm Sci. 2021;11(2):019\u201328.","journal-title":"J Appl Pharm Sci"},{"issue":"4","key":"3234_CR232","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00210-018-1474-8","volume":"391","author":"S Palle","year":"2018","unstructured":"Palle S, Neerati P. Improved neuroprotective effect of resveratrol nanoparticles as evinced by abrogation of rotenone-induced behavioral deficits and oxidative and mitochondrial dysfunctions in rat model of Parkinson\u2019s disease. Naunyn-Schmiedebergs Arch Pharmacol. 2018;391(4):445\u201353.","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"5","key":"3234_CR233","doi-asserted-by":"publisher","DOI":"10.3390\/nano12050758","volume":"12","author":"ACV de Guzman","year":"2022","unstructured":"de Guzman ACV, Razzak MA, Cho JH, Kim JY, Choi SS. Curcumin-loaded human serum albumin nanoparticles prevent Parkinson\u2019s disease-like symptoms in C. elegans. Nanomaterials. 2022;12(5):758.","journal-title":"Nanomaterials"},{"key":"3234_CR234","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S479959","author":"V Vestuto","year":"2024","unstructured":"Vestuto V, Conte M, Vietri M, Mensitieri F, Santoro V, Di Muro A, et al. Multiomic profiling and neuroprotective bioactivity of Salvia hairy root-derived extracellular vesicles in a cellular model of Parkinson\u2019s disease. Int J Nanomedicine. 2024. https:\/\/doi.org\/10.2147\/IJN.S479959.","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"3234_CR235","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2174\/0126673878279656231204103855","volume":"18","author":"K Lavania","year":"2024","unstructured":"Lavania K, Garg A. Ion-activated in situ gel of gellan gum containing Chrysin for nasal administration in Parkinson\u2019s disease. Recent Advances in Drug Delivery and Formulation: Formerly Recent Patents on Drug Delivery & Formulation. 2024;18(1):35\u201349.","journal-title":"Recent Advances in Drug Delivery and Formulation: Formerly Recent Patents on Drug Delivery & Formulation"},{"issue":"2","key":"3234_CR236","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12668-025-01834-5","volume":"15","author":"A Fadnis","year":"2025","unstructured":"Fadnis A, Mhaske A, Shukla R. Neuroprotective potential of Baicalin nanocrystals: optimisation, comprehensive in vitro SH-SY5Y cell studies and in vivo pharmacokinetics. BioNanoScience. 2025;15(2):1\u201315.","journal-title":"BioNanoScience"},{"issue":"1","key":"3234_CR237","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1166\/sam.2020.3594","volume":"12","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Zhong M, Wang J, Xia D, Bao J. Synthesis of baicalein modified cerium oxide nanoparticles for inhibitory activation of NF-\u03baB and mitogen-activated protein kinase signals in rotenone-induced Parkinsonian rats. Sci Adv Mater. 2020;12(1):93\u2013100.","journal-title":"Sci Adv Mater"},{"issue":"11","key":"3234_CR238","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1021\/acs.molpharmaceut.6b00644","volume":"13","author":"T Chen","year":"2016","unstructured":"Chen T, Li C, Li Y, Yi X, Lee SM-Y, Zheng Y. Oral delivery of a nanocrystal formulation of schisantherin A with improved bioavailability and brain delivery for the treatment of Parkinson\u2019s disease. Mol Pharm. 2016;13(11):3864\u201375.","journal-title":"Mol Pharm"},{"key":"3234_CR239","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1007\/s11095-013-1005-8","volume":"30","author":"R Huang","year":"2013","unstructured":"Huang R, Ma H, Guo Y, Liu S, Kuang Y, Shao K, et al. Angiopep-conjugated nanoparticles for targeted long-term gene therapy of Parkinson\u2019s disease. Pharm Res. 2013;30:2549\u201359.","journal-title":"Pharm Res"},{"issue":"1\u20132","key":"3234_CR240","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jns.2009.09.032","volume":"290","author":"R Huang","year":"2010","unstructured":"Huang R, Ke W, Liu Y, Wu D, Feng L, Jiang C, et al. Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model. J Neurol Sci. 2010;290(1\u20132):123\u201330.","journal-title":"J Neurol Sci"},{"issue":"2","key":"3234_CR241","doi-asserted-by":"publisher","first-page":"344","DOI":"10.7150\/thno.16562","volume":"7","author":"S Niu","year":"2017","unstructured":"Niu S, Zhang L-K, Zhang L, Zhuang S, Zhan X, Chen W-Y, et al. Inhibition by multifunctional magnetic nanoparticles loaded with alpha-synuclein RNAi plasmid in a Parkinson\u2019s disease model. Theranostics. 2017;7(2):344.","journal-title":"Theranostics"},{"key":"3234_CR242","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1007\/s12035-018-1109-6","volume":"56","author":"AE-E Aly","year":"2019","unstructured":"Aly AE-E, Harmon BT, Padegimas L, Sesenoglu-Laird O, Cooper MJ, Waszczak BL. Intranasal delivery of pGDNF DNA nanoparticles provides neuroprotection in the rat 6-hydroxydopamine model of Parkinson\u2019s disease. Mol Neurobiol. 2019;56:688\u2013701.","journal-title":"Mol Neurobiol"},{"key":"3234_CR243","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.omtn.2017.08.013","volume":"9","author":"C Helmschrodt","year":"2017","unstructured":"Helmschrodt C, H\u00f6bel S, Sch\u00f6niger S, Bauer A, Bonicelli J, Gringmuth M, et al. Polyethylenimine nanoparticle-mediated siRNA delivery to reduce \u03b1-Synuclein expression in a model of Parkinson\u2019s disease. Molecular Therapy-Nucleic Acids. 2017;9:57\u201368.","journal-title":"Molecular Therapy-Nucleic Acids"},{"key":"3234_CR244","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.biomaterials.2014.10.068","volume":"38","author":"T-E Park","year":"2015","unstructured":"Park T-E, Singh B, Li H, Lee J-Y, Kang S-K, Choi Y-J, et al. Enhanced BBB permeability of osmotically active poly (mannitol-co-PEI) modified with rabies virus glycoprotein via selective stimulation of caveolar endocytosis for RNAi therapeutics in Alzheimer\u2019s disease. Biomaterials. 2015;38:61\u201371.","journal-title":"Biomaterials"},{"issue":"5","key":"3234_CR245","doi-asserted-by":"publisher","first-page":"8592","DOI":"10.1021\/acsnano.1c00453","volume":"15","author":"J Garc\u00eda-Pardo","year":"2021","unstructured":"Garc\u00eda-Pardo J, Novio F, Nador F, Cavaliere I, Su\u00e1rez-Garc\u00eda S, Lope-Piedrafita S, et al. Bioinspired theranostic coordination polymer nanoparticles for intranasal dopamine replacement in Parkinson\u2019s disease. ACS Nano. 2021;15(5):8592\u2013609.","journal-title":"ACS Nano"},{"key":"3234_CR246","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103923","volume":"77","author":"S Raman","year":"2022","unstructured":"Raman S, Khan AA, Mahmood S. Nose to brain delivery of selegiline loaded PLGA\/lipid nanoparticles: synthesis, characterisation and brain pharmacokinetics evaluation. J Drug Deliv Sci Technol. 2022;77:103923.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3234_CR247","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.101724","volume":"57","author":"KS Shamarekh","year":"2020","unstructured":"Shamarekh KS, Gad HA, Soliman ME, Sammour OA. Development and evaluation of protamine-coated PLGA nanoparticles for nose-to-brain delivery of tacrine: in-vitro and in-vivo assessment. J Drug Deliv Sci Technol. 2020;57:101724.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"4","key":"3234_CR248","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s10876-023-02528-2","volume":"35","author":"Y Garg","year":"2024","unstructured":"Garg Y, Kumar M, Sharma G, Katare OP, Chopra S, Bhatia A. Systematic designing and optimization of polymeric nanoparticles using central composite design: a novel approach for nose-to-brain delivery of donepezil hydrochloride. J Cluster Sci. 2024;35(4):1007\u201319.","journal-title":"J Cluster Sci"},{"issue":"3","key":"3234_CR249","first-page":"297","volume":"1","author":"M Laura Immordino","year":"2006","unstructured":"Laura Immordino M, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed. 2006;1(3):297\u2013315.","journal-title":"Int J Nanomed"},{"issue":"1","key":"3234_CR250","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","volume":"65","author":"TM Allen","year":"2013","unstructured":"Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36\u201348.","journal-title":"Adv Drug Deliv Rev"},{"key":"3234_CR251","doi-asserted-by":"crossref","unstructured":"Cevc G. Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. Critical reviews\u2122 in therapeutic drug carrier systems. 1996;13(3\u20134):257\u2013388.","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v13.i3-4.30"},{"issue":"2","key":"3234_CR252","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","volume":"161","author":"F Danhier","year":"2012","unstructured":"Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Pr\u00e9at V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505\u201322.","journal-title":"J Control Release"},{"issue":"3","key":"3234_CR253","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/polym3031377","volume":"3","author":"HK Makadia","year":"2011","unstructured":"Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011;3(3):1377\u201397.","journal-title":"Polymers"},{"key":"3234_CR254","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2012.09.021","volume":"64","author":"W Mehnert","year":"2012","unstructured":"Mehnert W, M\u00e4der K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2012;64:83\u2013101.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1\u20132","key":"3234_CR255","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0378-5173(02)00180-1","volume":"242","author":"R M\u00fcller","year":"2002","unstructured":"M\u00fcller R, Radtke M, Wissing S. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 2002;242(1\u20132):121\u20138.","journal-title":"Int J Pharm"},{"issue":"3","key":"3234_CR256","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1039\/C0CS00018C","volume":"40","author":"N Khlebtsov","year":"2011","unstructured":"Khlebtsov N, Dykman L. Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chem Soc Rev. 2011;40(3):1647\u201371.","journal-title":"Chem Soc Rev"},{"issue":"18","key":"3234_CR257","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1016\/j.biomaterials.2004.10.012","volume":"26","author":"AK Gupta","year":"2005","unstructured":"Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005;26(18):3995\u20134021.","journal-title":"Biomaterials"},{"issue":"2","key":"3234_CR258","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nmat2608","volume":"9","author":"P Horcajada","year":"2010","unstructured":"Horcajada P, Chalati T, Serre C, Gillet B, Sebrie C, Baati T, et al. Porous metal\u2013organic-framework nanoscale carriers as a potential platform for drug delivery and imaging. Nat Mater. 2010;9(2):172\u20138.","journal-title":"Nat Mater"},{"issue":"14","key":"3234_CR259","doi-asserted-by":"publisher","first-page":"6060","DOI":"10.1039\/c3cs35486e","volume":"42","author":"H Wei","year":"2013","unstructured":"Wei H, Wang E. Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes. Chem Soc Rev. 2013;42(14):6060\u201393.","journal-title":"Chem Soc Rev"},{"issue":"1","key":"3234_CR260","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0169-409X(96)00490-5","volume":"25","author":"CW Pouton","year":"1997","unstructured":"Pouton CW. Formulation of self-emulsifying drug delivery systems. Adv Drug Deliv Rev. 1997;25(1):47\u201358.","journal-title":"Adv Drug Deliv Rev"},{"key":"3234_CR261","doi-asserted-by":"publisher","unstructured":"Wilde M. Effects of PAMAM dendrimers on model and biological membranes: University of Reading. 2021. https:\/\/doi.org\/10.48683\/1926.00103264.","DOI":"10.48683\/1926.00103264"},{"issue":"2","key":"3234_CR262","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1021\/tx400385x","volume":"27","author":"AB Seabra","year":"2014","unstructured":"Seabra AB, Paula AJ, De Lima R, Alves OL, Dur\u00e1n N. Nanotoxicity of graphene and graphene oxide. Chem Res Toxicol. 2014;27(2):159\u201368.","journal-title":"Chem Res Toxicol"},{"issue":"4","key":"3234_CR263","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.apsb.2016.02.001","volume":"6","author":"D Ha","year":"2016","unstructured":"Ha D, Yang N, Nadithe V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm Sin B. 2016;6(4):287\u201396.","journal-title":"Acta Pharm Sin B"},{"key":"3234_CR264","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11095-015-1784-1","volume":"33","author":"A Gothwal","year":"2016","unstructured":"Gothwal A, Khan I, Gupta U. Polymeric micelles: recent advancements in the delivery of anticancer drugs. Pharm Res. 2016;33:18\u201339.","journal-title":"Pharm Res"},{"issue":"7","key":"3234_CR265","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3109\/21691401.2015.1129617","volume":"44","author":"M Rahman","year":"2016","unstructured":"Rahman M, Kumar V, Beg S, Sharma G, Katare OP, Anwar F. Emergence of liposome as targeted magic bullet for inflammatory disorders: current state of the art. Artif Cells Nanomed Biotechnol. 2016;44(7):1597\u2013608.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"3234_CR266","doi-asserted-by":"crossref","unstructured":"Thurner GC, Chabicovsky M, Abdelmoez A, Debbage P. Targeted drugs and nanomedicine: present and future. Front Med Chem. 2016;9:182\u2013233.","DOI":"10.2174\/9781681082493116090008"},{"issue":"2","key":"3234_CR267","doi-asserted-by":"publisher","first-page":"143","DOI":"10.15171\/apb.2016.021","volume":"6","author":"LAS Bahari","year":"2016","unstructured":"Bahari LAS, Hamishehkar H. The impact of variables on particle size of solid lipid nanoparticles and nanostructured lipid carriers; a comparative literature review. Adv Pharm Bull. 2016;6(2):143-151.","journal-title":"Adv Pharm Bull"},{"issue":"03","key":"3234_CR268","first-page":"4891","volume":"6","author":"P Patil","year":"2016","unstructured":"Patil P, Wagh M, Chaudhari S. Potential of PLGA as a biodegradable polymer in novel drug delivery: a review. Indo Am J Pharm Res. 2016;6(03):4891\u20138.","journal-title":"Indo Am J Pharm Res"},{"key":"3234_CR269","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-016-0193-x","volume":"14","author":"E Piktel","year":"2016","unstructured":"Piktel E, Niemirowicz K, W\u0105tek M, Wollny T, Deptu\u0142a P, Bucki R. Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapy. J Nanobiotechnology. 2016;14:1\u201323.","journal-title":"J Nanobiotechnology"},{"issue":"3","key":"3234_CR270","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.tiv.2009.12.001","volume":"24","author":"E-J Park","year":"2010","unstructured":"Park E-J, Yi J, Kim Y, Choi K, Park K. Silver nanoparticles induce cytotoxicity by a trojan-horse type mechanism. Toxicol In Vitro. 2010;24(3):872\u20138.","journal-title":"Toxicol In Vitro"},{"issue":"1","key":"3234_CR271","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.colsurfb.2009.08.044","volume":"75","author":"M Mahmoudi","year":"2010","unstructured":"Mahmoudi M, Simchi A, Imani M, Shokrgozar MA, Milani AS, H\u00e4feli UO, Stroeve P. A new approach for the in vitro identification of the cytotoxicity of superparamagnetic iron oxide nanoparticles. Colloids Surf, B. 2010;75(1):300\u20139.","journal-title":"Colloids Surf, B"},{"key":"3234_CR272","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511919893","volume-title":"The toxicology of carbon nanotubes","author":"K Donaldson","year":"2012","unstructured":"Donaldson K. The toxicology of carbon nanotubes. Cambridge University Press; 2012."},{"key":"3234_CR273","doi-asserted-by":"crossref","unstructured":"Batool M, Tawakkul N, Batool S, Zafar MN, Nazar MF. Porous metal\u2013organic framework nanoscale carriers as a potential platform for drug delivery. Novel platforms for drug delivery applications: Elsevier; 2023. p. 153\u201376.","DOI":"10.1016\/B978-0-323-91376-8.00015-X"},{"issue":"4","key":"3234_CR274","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1039\/C8CS00457A","volume":"48","author":"J Wu","year":"2019","unstructured":"Wu J, Wang X, Wang Q, Lou Z, Li S, Zhu Y, et al. Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes (II). Chem Soc Rev. 2019;48(4):1004\u201376.","journal-title":"Chem Soc Rev"},{"issue":"1","key":"3234_CR275","first-page":"55","volume":"38","author":"S Arslan","year":"2013","unstructured":"Arslan S, Tirnaksiz F. Self-emulsifying drug delivery systems. FABAD J Pharm Sci. 2013;38(1):55\u201364.","journal-title":"FABAD J Pharm Sci"},{"key":"3234_CR276","unstructured":"https:\/\/patents.google.com\/patent\/CN113307970B\/en. Accessed 30 Sept 2025."},{"key":"3234_CR277","unstructured":"https:\/\/patents.google.com\/patent\/CN107693538B\/en. Accessed 30 Sept 2025."},{"key":"3234_CR278","unstructured":"https:\/\/patents.google.com\/patent\/US11899024B2\/en. Accessed 30 Sept 2025."},{"key":"3234_CR279","unstructured":"https:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=AU219608369. Accessed 30 Sept 2025."},{"key":"3234_CR280","unstructured":"https:\/\/patents.google.com\/patent\/US20080206146A1\/en. Accessed 30 Sept 2025."},{"key":"3234_CR281","unstructured":"https:\/\/patents.google.com\/patent\/US11529443B2\/en. Accessed 30 Sept 2025."},{"key":"3234_CR282","unstructured":"https:\/\/patents.google.com\/patent\/US10729717B2\/en. Accessed 30 Sept 2025."},{"key":"3234_CR283","unstructured":"UT Southwestern Medical Center. Gold nanoparticles show promise in reversing brain deficits from Parkinson\u2019s disease. 2024. https:\/\/www.utsouthwestern.edu\/newsroom\/articles\/year-2024\/feb-gold-nanoparticles-brain-deficits.html. [Internet]. Accessed 30 Sept 2025."},{"key":"3234_CR284","unstructured":"The Michael J. Fox Foundation. (n.d.). Cerium oxide nanoparticles for the treatment of Parkinson\u2019s disease. https:\/\/www.michaeljfox.org\/grant\/cerium-oxide-nanoparticles-treatment-parkinsons-disease. [Internet]. Accessed 30 Sept 2025."},{"key":"3234_CR285","volume":"8","author":"JH Kordower","year":"2022","unstructured":"Kordower JH, Fiandaca MS, Freeman TB. GM1 ganglioside therapy in Parkinson\u2019s disease: past, present, and future. NPJ Parkinsons Dis. 2022;8:107.","journal-title":"NPJ Parkinsons Dis"},{"key":"3234_CR286","unstructured":"https:\/\/www.researchnester.com\/reports\/parkinsons-disease-treatment-market\/7204?utm) [Internet]. Accessed 30 Sept 2025."},{"key":"3234_CR287","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.bbi.2021.07.026","volume":"98","author":"V Leta","year":"2021","unstructured":"Leta V, Chaudhuri KR, Milner O, Chung-Faye G, Metta V, Pariante CM, Borsini A. Neurogenic and anti-inflammatory effects of probiotics in Parkinson\u2019s disease: a systematic review of preclinical and clinical evidence. Brain Behav Immun. 2021;98:59\u201373.","journal-title":"Brain Behav Immun"},{"key":"3234_CR288","doi-asserted-by":"crossref","unstructured":"Kesharwani P, Jain A, Jain S, Dave V, Sharma S. Colloidosome as an efficient novel drug delivery system: an update. Advanced pharmaceutical and herbal nanoscience for targeted drug delivery systems Part II: Bentham Science Publishers. 2022;25:141\u201365.","DOI":"10.2174\/9789815036541122010010"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03234-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-025-03234-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03234-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T19:03:15Z","timestamp":1770318195000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-025-03234-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":288,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3234"],"URL":"https:\/\/doi.org\/10.1208\/s12249-025-03234-0","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author declares no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"9"}}